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Introduction 
No significant changes occurred in national or inter-
national cooperation in the surveillance and preven-
tion of infectious diseases in 2011.
An important change for the surveillance on antimi-
crobial susceptibility in 2011 was the introduction of 
the EUCAST (European Committee on Antimicro-
bial Susceptibility Testing) breakpoints instead of the 
previously used US breakpoints.
To enhance the surveillance of infectious diseases, 
geographically representative information on health 
care visits due to infections is needed. The collect-
ing of this information is enabled by the AvoHILMO 
system, a repository of data on the causes for health 
care visits in primary health care compiled and up-
dated on a daily basis. The component systems are 
undergoing rapid development, as major IT system 
suppliers are adding the required functions to the 
new software versions to be deployed. What is vital 
for achieving high-quality monitoring is to imple-
ment comprehensive registration and correct encod-
ing of reasons for health care visits as a part of routine 
reception procedure.
epidemiological oveRview 2011 
The influenza epidemic of winter 2010–2011, from 
December to March, was caused by the influenza 
A(H1N1)pdm09 virus, also known as the swine flu 
virus, which, after its first outbreak in Finland in early 
autumn 2009, returned at the time of the usual sea-
sonal influenza epidemic. The lower number of labo-
ratory-confirmed influenza A infections was probably 
due to the immunity conferred by the pandemic vac-
cinations of 2009 (coverage 51%) or by an earlier in-
fection. A record number of cases of influenza B were 
noted. The number of cases of whooping cough in-
creased on previous years, indicating incomplete pro-
tection by vaccination in the population. The myco-
plasma epidemic that began late in 2010 continued 
throughout 2011. 
The number of rotavirus cases among children under 
the age of 5 was half that of the previous year, prob-
ably because of the effect of the recently inroduced 
rotavirus vaccine. The number of cases of listeria also 
decreased, and the variant that had previously been 
the most commonly found in fish products almost 
completely disappeared. Salmonella Oranienburg 
caused several clusters around Finland.
The number of acute hepatitis A and B infections has 
remained very low; the situation with hepatitis C is 
unchanged.
More cases of gonorrhoea were noted than at any 
time in the 2000s, and the fluoroquinolone resistance 
of the pathogen remains high. More than half of the 
patients diagnosed with HIV infections were foreign-
ers; the majority of them had been infected through 
sexual contact. Most HIV infections are discovered 
at a late stage.
There were more MRSA blood culture findings than 
in the previous year, and the number of ESBL blood 
culture findings also increased on 2010.
Tuberculosis continues to present mainly in the eld-
erly Finns, their infections contracted decades earlier 
becoming active. One out of four cases of tuberculo-
sis were found among immigrants. The incidence of 
tuberculosis among children under the age of 5 has 
not increased since 2006, when the BCG vaccine was 
restricted to at-risk groups.
There was a considerably larger number of cases of mea-
sles than in previous years. Most of these were cases im-
ported from Europe. The number of cases of tick-borne 
encephalitis (TBE) increased, but detailed assessment 
of the cases revealed that a substantial number of the 
cases reported as TBE were found not to be TBE after 
careful evaluation of clinical history and laboratory re-
sults. These cases will be removed from the National 
Infectious Diseases Register (NIDR). The number of 
borrelia infections reached a new all-time high since 
NIDR monitoring began in 1995.
Most malaria cases originated in Africa. Dengue fever 
cases have been on the increase in recent years.
The number of cases of serious infection among 
adults confirmed by blood culture continued to grow. 
Preliminary analyses show that, following the intro-
duction of the pneumococcal conjugate vaccine in 
the national vaccination programme, severe pneumo-
coccal infections in small children found in blood or 
CSF decreased substantially in 2011 compared with 
previous years. 
Helsinki, 30 April 2012 
Petri Ruutu 
Head of Department
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Respiratory infections
The influenza A epidemic proved to be less severe than in the previous season, • 
2009–2010.
A record number of cases of influenza B were noted, most of them in February • 
and March.
The number of cases of whooping cough was higher than in the previous year. • 
Cases among infants indicate incomplete protection from vaccination in the 
population.
A record number of cases of • Mycoplasma pneumoniae was noted between 
October and December.
influenza
The influenza season began relatively early in 
2010–2011. Following isolated findings of influenza 
A and B in November, both the influenza A epidem-
ic and the influenza B epidemic began in December 
2010. 
influenza a 
Findings of influenza A reported to the NIDR indicate 
that the epidemic proper occurred between Decem-
ber 2010 and March 2011. The influenza A epidemic 
proved to be milder though longer than in the pre-
vious season, 2009–2010, when the pandemic wave 
occurred between October and December 2009. For 
the second season in a row, the influenza A(H1N1)
pdm09 virus proved to be the epidemic pathogen in 
winter 2010–2011. The lower number of laboratory-
confirmed influenza A infections was probably due 
to the immunity conferred by the pandemic vaccina-
tions of 2009 (Pandemrix; coverage about 51%) or 
by an earlier infection. 
In 2011, 1,900 findings of influenza A virus were re-
ported to the NIDR, of which 666 were laboratory-
confirmed findings of pandemic influenza A(H1N1)
pdm09. The national influenza centre at the National 
Institute for Health and Welfare recorded 177 influ-
enza A infections in 2011, of which 92% were caused 
by the influenza A(H1N1)pdm09 virus. The low 
number of cases of influenza A(H1N1)pdm09 virus 
infections reported to the NIDR is probably due to 
the fact that laboratories did not do as many virus 
sub-typings or send as many virus samples to be sub-
typed as during the pandemic. 
Most frequently influenza A(H1N1)pdm09 infec-
tions was occured among young adults (aged 15 to 
24). This may partly be explained by the fact that this 
age group had a lower vaccine coverage than the pop-
ulation on average and by the fact that surveillance 
locations for most influenza infections were at gar-
risons, where people of this age are undergoing mili-
tary service. 
During 2011, the genetic diversity of the influenza 
A(H1N1)pdm09 virus continued to grow. The epi-
demic pathogens of the influenza A(H1N1)pdm09 
group constituted seven distinct genetic groups, of 
which five were found in Finland. No significant an-
tigenic differences have been noted between these 
genetic groups and the vaccine virus, A/Califor-
nia/07/2009. The immunity conferred by the vaccine 
or a prior infection to influenza A(H1N1)pdm09 vi-
rus strains may be considered to have been good. 
Although a considerable proportion of the influenza 
A infections diagnosed proved to have been caused 
by influenza A(H1N1)pdm09 virus strains, isolated 
cases of influenza A(H3N2) subtype were noted in 
Finland at the beginning of 2011 and especially to-
wards the end of the year. The influenza A(H3N2) vi-
rus strains found are in a different genetic group than 
the vaccine virus, A/Perth/16/2009 H3N2. Antigenic 
differences were found between these virus groups. 
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Figure 1. Cases of influenza A by epidemic virus type per month, 2000–2011 (no. of cases).
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influenza b
In 2011, a record-breaking 3,444 cases of influenza B 
were reported to the NIDR (2010:140), of which the 
vast majority occurred in February or March (78%). 
The previous significant influenza B epidemic oc-
curred in 2008, with 1,775 cases of influenza B re-
corded. Infections were found in all age groups, but 
above all in the age groups of children aged 5 to 14 
and adults aged 30 to 44. The incidence was highest 
in the hospital districts of Southwest Finland, Hel-
sinki and Uusimaa, and Satakunta. 
Of the two influenza B lineages circling the world, 
viruses of the Victoria lineage have been principal-
ly generating epidemics over the past two years. In 
2011, the Victoria lineage virus strains continued to 
be the dominant epidemic pathogens, although the 
incidence of Yamagata lineage virus strains in influen-
za B infections has increased. Virus strains from both 
the Victoria and the Yamagata lineages were found 
in Finland in 2011, the slight majority being from 
the former. Both lineages continued to be found 
throughout the influenza B epidemic. 
Because of international agreements, only one lineage 
of influenza B may be included in the seasonal influ-
enza vaccination. The other two virus components in 
the vaccine are influenza A viruses of subtypes H1N1 
and H3N2. For the last three years, the influenza B 
virus included in the vaccine has been from the Vic-
toria lineage, B/Brisbane/60/2008. The virus strains 
from the Victoria lineage found in Finland were 
both genetically and antigenically similar to the vac-
cine virus. By contrast, the protection conferred by 
the vaccine against virus strains from the Yamagata 
lineage found in Finland was probably weak, since 
the virus strains from the Yamagata lineage found 
in Finland were genetically and antigenically some-
what different from the Yamagata vaccine virus that 
was previously used in the vaccine in autumn 2008 
(B/Florida/4/2007). 
RSv
In 2011, 1,524 cases of RSV confirmed with labora-
tory tests were reported to the NIDR (2010: 2,597). 
In long-term surveillance, a major RSV epidemic has 
been observed in Finland every other winter, often 
starting in November or December. One was expect-
ed in winter 2009–2010, but it remained insignificant 
in scale and did not peak until March and April. It is 
suspected that the autumn 2009 pandemic delayed 
the onset of the RSV epidemic. That the number of 
cases recorded in 2011 was low was due to a minor 
spring epidemic in March and April and the larger 
winter epidemic not beginning until December. 
The incidence of RSV varied by hospital district 
(5–50/100,000), most likely caused by differences in 
the use of laboratory diagnostics. As always, nine out 
of ten RSV cases involved children aged 0 to 4. Even 
8
Report 38/2012
National Institute for Health and Welfare 
Infectious Diseases in Finland 2011
Figure 2. Cases of influenza B by epidemic virus type per month, 2000–2011 (no. of cases).
Figure 3. Cases of RSV per month, 2000–2011 (no. of cases).
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though infections occur in all age groups, babies and 
small children constitute the majority of cases leading 
to hospitalisation and laboratory diagnostics.
Reliable quick tests for RSV diagnostics have been 
developed for use at health centres, outpatient clin-
ics and hospitals. In hospital conditions, RSV is eas-
ily transmitted between patients. Quick tests make 
it easier to identify RSV infections and therefore to 
prevent further transmission. Specialised virus labo-
ratories increasingly use nucleid acid amplification 
methods for diagnosing RSV. 
legionella 
In 2011, 54 suspected findings of legionellosis were 
reported to the NIDR. The diagnosis was based on 
detection of antigen in the urine in 5 cases and in 
sputum in one case, on bronchoalveolar lavage fluid 
culture or PCR in 1 case, and on serological meth-
ods in the rest. Further study showed that the clinical 
presentation was consistent with legionella pneumo-
nia in only five cases. In all of these, the urine antigen 
test was positive (and in one case the culture too). All 
of the patients with legionella pneumonia were men 
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Figure 4. Cases of whooping cough in the children and young adult age groups, 2000–2011 (no. of cases). 
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aged between 51 and 63, and all had been abroad 
before falling ill. The accommodation data of these 
patients were reported to ELDSNET (European Le-
gionnaires’ Diseases Surveillance Network), which 
collects data on travel-associated legionellosis. 
Late in 2011, an epidemic consistent with a milder 
form of legionellosis, Pontiac fever, was noted in the 
Helsinki metropolitan area: 11 people who had all 
used the same jacuzzi or swimming pool suite pre-
sented with a fever within 2 to 4 days; elevated levels 
of legionella antibodies were found in eight of them. 
None of them was diagnosed with pneumonia. A 
strain of Legionella anisa bacterium was isolated from 
the water and surfaces of the jacuzzi, even though 
the water had apparently been appropriately chlorin-
ated. This bacterium rarely causes an illness. Keeping 
jacuzzis clean requires sufficiently high levels of chlo-
rine, continuous water circulation and regular clean-
ing. Corporate in-house jacuzzis use are not subject 
to mandatory regular inspections in Finland, unlike 
jacuzzis at public swimming halls and spas, which are 
monitored by the environmental health authorities. 
According to the most recent guidelines concerning 
legionella from the WHO and the EWGLI (Euro-
pean Working Group for Legionella Infections), all 
jacuzzis should inspected at least every three months 
for legionella bacteria. 
whooping cough 
In 2011, the number of whooping cough cases re-
ported to the NIDR totalled 555 (10/100,000). The 
number of cases was clearly higher than in 2010, 343 
(6/100,000). The cases were concentrated in the age 
groups of 10 to 24 and under 12 months. Fifty-three 
of the patients were under 12 months old, with 35 
under three months old. Illness in infancy indicates 
insufficient herd immunity. Until 2007, vaccinations 
in adolescence were given between the age of 11 and 
13. This was then raised to the age of 14 to 15. Be-
cause of the transition, very few vaccinations were 
given between 2009 and 2011. This created a tem-
porarily less well protected cohort in adolescent age 
groups, and consequently increased morbidity has 
been observed. It is recommended that vaccinations 
in adolescence be initiated in the 8th grade. 
The diagnosis of nearly all (49) patients under 12 
months old was based on a PCR test, while the major-
ity of cases were diagnosed by antibody testing. Once 
again, incidence of whooping cough varied greatly 
by hospital district (0–16/100,000), being highest in 
the hospital district of Helsinki and Uusimaa, while 
no cases at all were recorded on Åland. There was a 
whooping cough epidemic at Parolannummi garri-
son in autumn 2011. In 2011, the first discovery was 
made of strains of Bordetella pertussis that do not pro-
duce the vaccine antigen pertactin. The vaccine may 
be of weaker potency against these strains.
10
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adenoviRuS 
In 2011, almost 800 confirmed cases of adenovirus 
infection were recorded (2010: 900). The largest 
number of cases was in the age group of under 5, but 
there were also cases in the age groups 5 to 9, 15 to 19 
and 20 to 24. In terms of time, the largest numbers 
of cases were recorded in February and March (more 
than 100 cases per month) and towards the end of the 
year (about 70 per month). 
There are 57 known types of adenovirus. Some of 
them cause respiratory infections, while others cause 
intestinal, eye or other infections. Adenoviruses are 
common pathogens in infants and small children; 
they occur more rarely in adults. Adenovirus infec-
tions among conscripts tend to appear as epidemics 
whenever new arrivals enter service, particularly in 
February and March, i.e. after the annual influenza 
epidemic. However, in winter 2011 the adenovirus 
epidemic practically coincided with the influenza A 
and B epidemics in February and March. There were 
numerous adenovirus infections in several garrisons, 
some of them severe. In summer 2011, the adenovi-
rus situation was rather uneventful, but towards au-
tumn the frequency of infections increased again. 
Laboratories use various testing methods to detect 
adenoviruses in clinical samples. Antigen detection, 
virus cultures and PCR are sensitive and reliable 
methods used at specialised virus laboratories. 
paRainfluenza 
Parainfluenza viruses are grouped under one heading 
in the NIDR, even though laboratories usually dif-
ferentiate between parainfluenza viruses 1, 2 and 3. 
The number of confirmed parainfluenza infections 
in 2011 was 279 (2010: 393), most of them in the 
age group 0 to 4. The months with the highest num-
bers of cases (more than 50 per month) were Janu-
ary, February and March. Parainfluenza infections are 
found in all age groups. A child’s first parainfluenza 
infections may lead to a severe condition, even re-
quiring hospitalisation. In an older child or an adult, 
a parainfluenza infection is typically much milder in 
its symptoms. It often presents as an ordinary upper 
respiratory tract infection and requires no laboratory 
diagnostics. In special groups, however, such as im-
mune deficiency patients, parainfluenza viruses can 
cause quite serious symptoms. Parainfluenza virus 
type 3 causes minor epidemics in the summer and 
autumn nearly every year. By contrast, parainfluenza 
viruses types 1 and 2 do not cause epidemics every 
year. Parainfluenza viruses, especially type 1, typically 
cause laryngitis in small children. 
mycoplaSma 
In 2011, there were more than 7,800 laboratory-
confirmed cases of M. pneumoniae. Because of an 
increase in incidence noted during 2010 (peaking 
in March 2011), it was predicted that an epidem-
ic would emerge in the following winter too, since 
M. pneumoniae epidemics tend to be double-peaked. 
This prediction was fulfilled; the number of cases be-
gan to increase in autumn 2011, with record num-
bers reported to the NIDR between October and 
December (more than 3,700). Part of this growth is 
due to increased awareness and more frequent sam-
pling. A survey conducted by the National Institute 
for Health and Welfare indicates that the number of 
samples tested was up to four times higher than in 
the previous year, but then again there were also large 
numbers of clinical cases recorded at health care vis-
its. M. pneumoniae epidemics were also reported in 
the other Nordic countries, the UK and the Nether-
lands. 
Most of the reported cases were aged 5 to 19. Labora-
tory diagnoses were mostly based on IgM antibody 
detection. The largest number of cases was record-
ed in the hospital district of Helsinki and Uusimaa 
(about 2,500), but the incidence was highest in the 
Central Bothnia and Northern Savo hospital districts 
(>200/100,000). It has been noted in recent years in 
Asia in particular that M. pneumoniae has developed 
macrolide resistance. In Europe, this has been rela-
tively rare (about 3%). Nucleic acid detection meth-
ods are rarely used in M. pneumoniae diagnostics in 
Finland, and it has thus not been possible to study 
here whether strains of the bacteria are macrolide-
resistant. 
chlamydial pneumonia 
The number of cases of Chlamydia pneumoniae re-
corded in 2011 was 400, double the number in the 
previous year and four times as many as in 2009. 
This may be partly explained by increased testing: 
during the M. pneumoniae epidemic of 2011, many 
patients with respiratory symptoms were also tested 
for C. pneumoniae antibodies, as it is impossible to 
distinguish between these two infections on the basis 
of symptoms alone. The growth trend in the number 
of cases of C. pneumoniae that began in 2010 contin-
ued in 2011, and a unusually large number of cases 
was reported between January and April and between 
September and November. The incidence was highest 
in the Central Bothnia, Kainuu and Vaasa hospital 
districts (19–23/100,000), while the largest number 
of cases was recorded in the hospital district of Hel-
Report 38/2012
National Institute for Health and Welfare 
Infectious Diseases in Finland 2011
11
Figure 5. Cases of Mycoplasma pneumoniae and Chlamydia pneumoniae per month, 2000–2011 (no. of cases).
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sinki and Uusimaa (120). C. pneumoniae was most 
commonly found among children and adolescents 
(aged 5 to 19) and in the age group of 30 to 49. The 
diagnosis was based on antibody detection in nearly 
all cases.
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Intestinal infections
The • Salmonella Oranienburg bacterium caused clusters of intestinal infections all 
around Finland.
Half as many number of cases of rotavirus infection among children under the • 
age of 5 as in 2010.
Fewer cases of listeria were recorded than in the previous year. Only one case • 
caused by the most common type of Listeria bacterium found in fish products in 
the previous year (genotype 96) was recorded in 2011.
Salmonella
In 2011, there were 2,099 reported cases of salmonella 
(2010: 2,438), 55% of them in women patients. An-
nual incidence in the entire country was 39/100,000 
population. The incidence was highest in the hospital 
district of Lapland (57/100,000) and lowest in the 
hospital district of Southern Bothnia (23/100,000), 
and the highest number of cases was in the age group 
25 to 29. 
There were 5 diagnosed cases of the S. Typhi sero-
type, which causes typhoid and 3 cases of S. Para-
typhi, which causes paratyphoid: one each of S. Para-
typhi B, S. Paratyphi A and S. Paratyphi C. All pa-
tients had acquired the infection abroad. India was 
the most common sources for S. Typhi and S. Para-
typhi infections. 
Out of all cases of salmonella, 338 (18%) were of 
domestic origin, roughly the same percentage as in 
earlier years. The incidence of domestic infections 
was 6/100,000. Domestic salmonella infections were 
caused by 45 different serotypes. The leading four se-
rotypes were Typhimurium (25%), Enteritidis (14%), 
Oranienburg (13%) and Group B (12%). Unlike in 
previous years, a new sub-group has emerged within 
Group B: monophasic S. Typhimurium. In 2011, 
these strains accounted for 35 domestic cases (2010: 
5; 2009: 5). Most of the monophasic strains of Typh-
imurium found in 2011 belonged to the multiresist-
ant phage type FT 195 (resistance profile ASSuTe), 
for which a reservoir is not known to exist in domes-
tic production animals. Out of the rest of the domes-
tic cases of Typhimurium found, the majority (60%) 
were caused by the traditional endemic phage type 
FT 1. The second most common phage type (17%) 
was FT NST (not specific type). The FT 1 strains 
are divided into 12 genotypes, most of which (77%), 
as in previous years, were of the genotype STYM 1, 
which is susceptible to antimicrobials. All 87 domes-
tic Typhimurium strains were further typed using 
the MLVA method based on differences between re-
peated sequences in DNA; the majority of the strains 
in the domestic genotype STYM 1 (63%) presented 
with the MLVA profile 3-16-NA-NA-0311. 
There were 47 cases caused by the domestic Enteri-
tidis serotype. These were divided into 14 phage 
types, most of them (more than half ) of the types 
FT 8, FT 1, FT 4B and FT 2, and into 20 genotypes, 
the most common being SENT 1. 
Information on whether a salmonella infection was ac-
quired in Finland or abroad remained lacking for 150 
(7%) cases reported to the NIDR in 2011. The total 
number of foreign salmonella infections was 1,614. 
The salmonella infections acquired abroad represent-
ed 122 serotypes. The S. Enteritidis serotype caused 
612 (38%) of the cases with foreign origin. The next 
most common serotypes acquired abroad were Group 
B (144 cases), Typhimurium (80) and Stanley (68). 
The majority (71%) of the foreign cases caused by 
Group B were caused by the monophasic, multire-
sistant phage type FT 193 of S. Typhimurium (the 
most common resistance profile being ASSuTe and 
the most common source being Thailand). In the re-
maining foreign cases too, the most common source 
was Thailand (29%), followed by Turkey (13%), In-
dia (6%) and Egypt (6%). 
There were 564 strains phage-typed from the for-
eign S. Enteritidis strains and 72 from the S. Typh-
imurium strains. The most common phage types of 
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Table 1.  The most common serotypes of salmonella cases, 2000–2011 (excluding S. Typhi and S. Paratyphi) 
(no. of cases).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
infection acquired abroad (source: nidR)
Salmonella Enteritidis 1052 1243 904 887 758 834 879 735 1066 657 778 612
Salmonella group B 45 32 33 23 37 38 55 93 166 119 103 144
Salmonella Typhimurium 205 143 115 155 183 194 141 246 198 166 142 80
Salmonella Stanley 44 63 65 67 105 113 116 175 136 111 98 68
Salmonella Corvallis 7 21 10 40 39 60 56 59 70 68 42 45
Salmonella Virchow 50 79 55 67 74 88 80 135 115 90 77 32
Salmonella Abony 10 11 8 9 4 4 1 9 3 18 31 32
Salmonella Infantis 23 34 20 16 33 39 31 54 31 42 42 31
Salmonella Bareilly 9 17 6 8 5 17 19 18 27 14 18 27
Salmonella Weltevreden 12 10 11 5 12 14 15 25 14 36 14 27
Other 765 723 617 585 590 544 634 724 780 618 685 516
total 2222 2376 1844 1862 1840 1945 2027 2273 2606 1939 2030 1614
domestically acquired infections (source: bacteriology unit)
Salmonella Typhimurium 124 152 222 137 132 241 170 150 80 134 132 94
Salmonella Enteritidis 52 63 42 61 81 75 69 61 49 48 44 47
Salmonella Oranienburg 0 0 7 4 1 1 0 0 7 2 2 43
Salmonella group B 5 2 3 2 7 1 4 11 5 7 8 40
Salmonella group E 1 0 0 0 0 1 1 0 0 1 7 13
Salmonella Agona 27 41 16 12 27 32 11 40 15 2 2 11
Salmonella Infantis 7 19 4 4 4 11 6 3 7 2 9 10
Salmonella Napoli 0 1 0 3 2 0 2 0 2 0 6 6
Salmonella Newport 11 5 3 16 8 3 9 23 70 9 8 6
Salmonella Give 1 1 0 0 1 4 39 3 2 1 2 5
Salmonella Poona 8 1 4 9 0 2 5 0 14 12 8 5
Salmonella Senftenberg 1 4 0 0 0 1 0 1 0 0 5 5
Other 88 101 105 62 73 71 81 80 123 91 101 53
total 325 390 406 310 336 443 397 372 374 309 334 338
Figure 6. Salmonella and campylobacter cases per month, 2000–2011 (no. of cases).
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Figure 7. Yersinia enterocolitica culture and antibody findings, 2000–2011 (no. of cases).
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S. Enteritidis were FT 14B (18%; from 9 different 
countries, mostly Estonia, Turkey and Spain), FT 21 
(16%; from 17 countries, mostly Turkey) and FT 1 
(15%; from 17 countries, mostly Russia), while the 
most common phage types of S. Typhimurium were 
FT NST (22%; from 11 countries), FT 41 (18%; 
all from Mauritius) and FT 120 (13%; mostly from 
Thailand and Vietnam). 
campylobacteR 
In 2011, the NIDR received 4,251 notifications of 
campylobacter infections, 307 cases fewer than in 
2010. Campylobacter jejuni remained the single most 
common species of campylobacter (2,017 cases); 
there were 180 reported cases of C. coli, and no few-
er than 1,840 cases where the campylobacter species 
was not specified. The hippurat test used to distin-
guish between species has been abandoned in some 
laboratories, because it cannot correctly identify all 
strains. The incidence in the entire population was 
78/100,000. Men accounted for 54% of the cases, 
and the highest number of cases was in the age group 
20 to 49. Incidence was highest in the hospital dis-
trict of Helsinki and Uusimaa (122/100,000). 
The seasonal variation was typical for campylobacter: 
incidence was highest in July and August. (Figure 6) 
Of the cases in 2011, 547 (13%) were domestic in 
origin, although 40% of the cases lacked data on the 
country of acquisition. A total of 1,960 cases (46%) 
were reported to be associated with a trip abroad; 
the leading sources for these infections was Thailand 
(504 cases), followed by Turkey (269), Spain (242) 
and India (125).
yeRSinia
yersinia enterocolitica 
In 2011, the NIDR received 514 notifications of 
Yersinia enterocolitica, a 12% increase on 2010 
(458). In 2011, the incidence in the entire country 
was 10/100,000 population. Based on the cases re-
ported to the NIDR, the incidence was highest in 
the age group 45 to 54 (13/100,000) and lowest in 
the age group 10 to 14 (3/100,000). There is great 
regional variation in the Yersinia enterocolitica find-
ings. The incidence was highest in the hospital dis-
trict of Helsinki and Uusimaa and the Kainuu hos-
pital district (17/100,000) and lowest in the Eastern 
Savo and Western Bothnia hospital districts (less than 
2/100,000). 
Typing data were given for only about 35% of Y. en-
terocolitica cases in 2011, which makes it difficult to 
draw conclusions about the percentages of the various 
bio/serotypes. However, the majority of the types re-
ported were of the non-pathogenic biotype 1A (26% 
of all cases of Y. enterocolitica). A separate study found 
that Y. enterocolitica bacteria isolated from elderly pa-
tients tend to be non-pathogenic strains, while path-
ogenic strains are over-represented in small children. 
Yersinia strains may be sent to the National Institute 
for Health and Welfare for typing if necessary. In 
November and December 2011, an unusually large 
number of Y. enterocolitica strains of the serotype O:9 
were sent to the National Institute for Health and 
Welfare. These strains came from 10 different per-
sons, about half of whom were from eastern Finland. 
In the previous year, the same serotype was isolated 
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Figure 8. Yersinia pseudotuberculosis culture and antibody findings, 2000–2011 (no. of cases).
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in 7 patients in Leppävirta in eastern Finland; in the 
outbreak in question, 42 patients developed gastroin-
testinal symptoms. 
yersinia pseudotuberculosis 
The number of Yersinia pseudotuberculosis cases (28 
cases) continued to decrease, having been 58 in 2010. 
In 2011, the incidence in the entire country was 
0.5/100,000 population. The number of cases is too 
low to reliably indicate any regional variation, and 13 
hospital districts diagnosed no cases at all in 2011. 
Outbreaks cause variation in the annual incidence of 
cases of Y. pseudotuberculosis. 
Shigella
In 2011, the incidence of shigellosis was 3.0/100,000. 
There were 127 reported cases, 50 in men and 77 in 
women. The median age of patients was 41 (range 1 
to 79), with a very small percentage of patients un-
der the age of 20 (15 cases) or over the age of 65 
(7 cases). About half of the cases (63) were reported 
in the hospital district of Helsinki and Uusimaa. Six 
hospital districts had no diagnosed cases. Of the total, 
123 infections (97%) were acquired abroad and 3 in 
Finland. In one case, the country of acquisition was 
not specified. Three of the patients presented simul-
taneously with a Salmonella infection, one had an 
infection caused by two different species of Shigella, 
and one patient had evidently caught one infection 
in India in May or June and another one in Nepal 
in November (different strains). The most common 
countries of origin were Egypt (42 cases) and India 
(30). The prevailing Shigella species were Shigella son-
nei (84 cases), followed by S. flexneri (24) and S. boy-
dii (6). There were 5 reported cases of S. dysenteriae 
(no shigatoxin-producing serotypes were among the 
pathogens). Of all Shigella strains, 79% were multire-
sistant (R to at least 4 out of 12 antimicrobials tested), 
and 34% were completely resistant or had reduced 
susceptibility to ciprofloxacin (MIC 0.125–12 mg/l). 
Moreover, 6 strains were completely resistant to ce-
photaxim (some are estimated to produce ESBL en-
zyme). 
enteRohaemoRRhagic 
escHeRicHia coli (eHec) 
In 2011, 27 microbiologically confirmed cases of 
enterohaemorrhagic Escherichia coli (EHEC) were 
reported to the NIDR (0.5/100,000). This is more 
than in 2010 (20). Foreign acquisition accounted for 
5 of the cases. There were 11 women and 16 men. 
The patients were under the age of 15 in 18 cases, 
11 of them under the age of 5. The majority of diag-
noses were made between June and September. Farm 
contact was involved in 9 cases. Six patients suffered 
from haemolytic-uremic syndrome as a complica-
tion. Five small clusters of infections were identified 
among people who lived in the same household or 
had otherwise been in close contact with the origi-
nal patients. One of the cases was connected with the 
outbreak of EHEC-EAEC O104:H4 in Germany 
spread through fenugreek sprouts, where more than 
4,200 people fell ill. 
The O157-serogroup strains were divided into two 
common phage types (FT 8 and FT 88) and caused 
a total of 11 cases. There were 16 cases of serogroup 
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Figure 9. Cases of norovirus infection per month, 2005–2011 (no. of cases).
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Non-O157. The strains isolated from these were 
typed into the O groups O26, O104, O121, O145 
and O91. The O antigen remained untyped for two 
strains (ONT). Most of the strains had the genes to 
produce either Stx2 shigatoxin or both Stx1 and Stx2 
shigatoxin. 
noRoviRuS 
In 2011, 1,591 cases of norovirus were reported, clearly 
less than the annual numbers between 2006 and 2010; 
931 (59%) of the cases were in women. 70% of the 
cases were reported between January and April. More 
than half (58%) of the patients were over 75 years of 
age, but infections were diagnosed in all age groups. 
Cases were reported in all hospital districts. 
The year 2011 was the fifth year running when new 
variants of the norovirus GII.4 genotype, emerging 
every one or two years, caused a widespread epidemic 
in Finland, as indeed they did elsewhere in the world. 
As in previous years (2007–2010), most of the out-
breaks that occurred in 2011 were institutional out-
breaks. This also explains the high incidence among 
the elderly. 
The norovirus outbreaks in 2011 were caused almost 
exclusively by norovirus variant GII.4 2010, which 
is a recombination of two earlier GII.4 variants that 
emerged in 2006 and 2008. In some cases, the patho-
gen proved to be an earlier, now rare norovirus variant 
GII.4 2006b or a newer variant GII.4 which on the 
basis of polymerase nucleic acid sequencing cannot be 
classified as any known variant of GII.4. There were 
also individual outbreaks caused by other genotypes 
(GI.4, GI.b, GI.7, GII.b, GII.7, GII.g) in 2011. 
Norovirus has become one of the most common 
causes of food- or water-borne outbreaks in the 
2000s. In 2011, food-borne outbreaks were caused 
by noroviruses of both genogroup I (GI.3, GI.4) and 
genogroup II (GII.7, GII.4 2010). 
RotaviRuS 
Only 292 cases of rotavirus were reported in 2011, 
one fifth of the average annual number before the in-
troduction of rotavirus vaccines. Rotavirus vaccines 
began to be supplied by pharmacies in summer 2006. 
The vaccine was initially underused, but by 2008 one 
child in three was receiving a rotavirus vaccination, 
paid for by the parents. The rotavirus vaccine was fi-
nally added to the national vaccination programme 
in September 2009. 
The incidence was again clearly highest in children un-
der five years of age (63/100,000), but this was half of 
the figure in the previous year. Before the addition of 
the vaccine to the vaccination programme, the inci-
dence in this age group on average was 460/100,000. 
In other words, the incidence in 2011 was less than 
15% of that figure. With increasing vaccination of in-
fants, the proportion of cases in older age groups will 
increase. In 2011, over one third of all cases were in 
patients aged 5 or over, whereas this figure was never 
higher than about 10% in previous years.
In 2011, most of the cases were caused by rotavi-
rus serotypes G1P[8], G4P[8], G3P[8], G2P[4] and 
G9P[8]. The illnesses caused by the various serotypes 
are very similar. Rotavirus diagnoses are mainly based 
on quick tests that do not indicate the type of virus. 
In the future, however, it will become increasingly 
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Figure 10. Cases of rotavirus by age groups 2005–2011 (no. of cases).
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important to identify the type of rotavirus so that it 
can be established which serotypes cause infections 
regardless of the vaccination. 
enteRoviRuS
In 2011, 219 enterovirus cases were reported to the 
NIDR, about half of the number reported in the epi-
demic year 2010 (560). Men accounted for 127 (58%) 
of the cases. Almost half (92, 42%) of the patients 
were under the age of 10, and the majority of cases 
involved patients under the age of 20. The epidemic 
season began fairly early, as in the previous year; cases 
began to emerge in May and June. Although various 
strains of Coxsackie A and B viruses and echoviruses 
circulated in the population in 2011, no major epi-
demic clusters were observed. CV-A2, CV-B3, echo-
virus 6, echovirus 18 and enterovirus 71 were found 
in patients diagnosed with encephalitis or meningitis 
or presenting with unspecific fever. Cases caused by 
CV-A6 and echovirus 30 were also recorded. CV-A16 
caused cases of hand, foot and mouth disease. 
Enteroviruses cause conditions such as aseptic menin-
gitis, encephalitis, myocarditis and typical enteroviral 
conditions (hand, foot and mouth disease, epidemic 
myalgia, etc.). Enterovirus diagnostics is increasingly 
based on the RT-PCR method, which does not distin-
guish between virus serotypes. Therefore, a stool cul-
ture remains the recommended and most useful way 
of diagnosing an enterovirus infection. Stool cultures 
also enable the monitoring of the possible circulation 
of polio viruses in the population; this monitoring is 
important and necessary even in Finland. 
liSteRia 
Listeria monocytogenes infections were lower in  number 
(44) than in the previous year. About half of the pa-
tients were over the age of 70; men and women were 
equally represented. No pregnancy-related cases were 
reported to the NIDR. The listeria cases were spread 
out across the country. The annual number of cases 
varied between 18 and 46 in the years 2000–2009; in 
2010, 71 cases were reported. 
Listeria was isolated from blood culture in 38 (88%) 
cases; in 6 cases, listeria was diagnosed from cerebro-
spinal fluid; for 4 of these, the diagnosis was con-
firmed by blood culture. The strains isolated from 
43 patients were sent for further typing; 28 of them 
(65%) were found to be of serotype 1/2a, 10 (23%) 
of serotype 4b, 3 (7%) of serotype 1/2b and 2 (5%) 
of serotype 1/2c. The strains comprised 34 different 
PFGE genotypes of listeria. 
In December 2010 and January 2011, four cases of 
listeriosis of genotype 62 were reported in Finland. 
All the patients were women aged over 80. All of 
them had access at their respective nursing homes at 
Christmas to gravad salmon prepared by a specific 
fish processing facility. A bacterial strain of genotype 
62 identical to that found in the patients was isolated 
from the gravad salmon served at one of the nurs-
ing homes involved, and production hygiene at the 
production facility was improved. In 2011, genotype 
62 was the most commonly found genotype, being 
found in 7 cases as opposed to one or two of each of 
the others. Genotype 62 has been found in the prod-
ucts of several fish producers. 
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In 2010, 71 serious cases of illness caused by liste-
ria were found in Finland. Two thirds of the patients 
interviewed said that they had eaten gravad or cold-
smoked fish. The most common type of listeria in 
these cases (genotype 96) was also the most com-
monly found type in foods in 2010. The majority of 
the findings came from a single fish processing facil-
ity, which was renovated. In 2011, genotype 96 was 
found in only one case. 
Listeria monocytogenes causes severe infections in in-
fants, pregnant women, patients with immune defi-
ciency and the elderly. This infection is food-borne; 
risk foods include products made of unpasteurised 
milk and other animal- or plant-based foodstuffs and 
ready-made foods that are in cold storage for a long 
time and eaten unheated. Finland’s risk foods include 
vacuum-packed salt-cured and cold-smoked fish prod-
ucts. Listeria bacteria may also occur in the food pro-
duction environment, contaminating food products 
after the heat treatment in the production process. 
cloStRidium difficile 
Clostridium difficile has been a finding reportable to 
the NIDR from the beginning of 2008. More than 
6,000 cases were reported in 2011 (2010: >6,000; 
2009: >7,000; 2008: >8,000), out of which 5,382 
(2010: 4,804; 2009: 5,700; 2008: 6,301) involved a 
toxin-producing strain. Almost 60% of patients di-
agnosed with C. difficile were women, and about half 
were 75 years of age or older. The number of toxin-
positive strains in patients under the age of 15 was 176 
(3%) (2008–2010: 2–3%), of which just under one 
in five were isolated in patients under the age of 12 
months. There was significant regional variation in the 
incidence (47–168/100,000), with the Kymenlaakso, 
Central Bothnia, Northern Bothnia and Satakunta 
hospital districts showing the highest incidence. 
In severe cases or when a local outbreak is suspected, 
clinical laboratories have been asked to send C. difficile 
strains for further examination by the THL reference 
laboratory. There continued to be great local varia-
tion in the number of strains sent: although all hos-
pital districts reported toxin-positive C. difficile cases, 
only 9 of them sent strains for genotyping. The to-
tal number of strains sent has been slightly declin-
ing, and last year accounted for less than 4% (194 
out of 5,382) of the number of cases reported. The 
194 strains typed at the THL in 2011 represented 
32 ribotypes. The most common ribotypes apart 
from 027 were 001, 014, 023 and 002. Severe cases 
were caused by ribotypes 027, 020, 014 and 002; lo-
cal clusters were caused by ribotypes 001, 002, 014, 
012 and 023. In addition to PCR ribotype 027, other 
ribotypes (023 and 078) were detected that may be 
possible hyper-producers of toxin. So far, more than 
90 different PCR ribotypes have been detected in 
Finland, of which about 30 have been identified as 
genotypes previously reported internationally. 
Significant inteStinal 
infection epidemicS
From the beginning of 2010, municipal epidemic 
investigation working groups entered notifications 
of suspected food- and water-borne epidemics di-
rectly into the register IT system jointly maintained 
by the National Institute for Health and Welfare and 
the Finnish Food Safety Authority Evira, known as 
the RYMY information system. In the course of the 
year, 86 such notifications were entered. Salmonella 
Oranienburg caused several clusters of outbreaks 
around Finland. Several other intestinal infection 
clusters were investigated as well. 
salmonella oranienburg epidemic in savo 
An outbreak of 41 cases of Salmonella Oranienburg 
was found beginning in early July, mainly in the re-
gions of Etelä-Savo and Pohjois-Savo. The three geno-
types identified in these cases (SORA 10, 25 and 26) 
were very similar, and the cases were therefore con-
sidered to be linked. The median age in these cases 
was 61 years, the range 7 to 90 years, and three out of 
five patients were men. More than half of the patients 
were related to each other in some way. The number 
of cases spiked in July and August compared with the 
rest of the year, and they were concentrated in the 
area around Pieksämäki, Varkaus and Leppävirta. The 
epidemic was investigated jointly by the National In-
stitute for Health and Welfare, Finnish Food Safety 
Authority Evira and the local authorities. The source 
of the infections was never established, but suspicion 
focused on local seasonal produce, specifically straw-
berries. No information was available on investiga-
tions to trace the strawberries. A sample was taken 
from frozen strawberries in one of the households 
where a case occurred, but no salmonella was found. 
salmonella oranienburg epidemic in 
Helsinki 
An outbreak of 15 cases of Salmonella Oranienburg, 
genotype SORA 27 (different from the one in Savo) 
was found in August and September, the linking fac-
tor being eating lunch at a Helsinki restaurant. The 
median age in these cases was 36 years, the range 25 
to 54 years, and most of the patients were men. The 
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epidemic was investigated jointly by the Helsinki En-
vironment Centre, the Helsinki Epidemiology Unit 
and the National Institute for Health and Welfare. 
Analysis showed that there was no correlation be-
tween the illness and any specific course or any spe-
cific time of day. The infections were probably caused 
by shortcomings in the restaurant’s own monitoring 
and standards of hygiene. 
cases of salmonella oranienburg in 
travellers returning from turkey 
Starting in June, cases of Salmonella Oranienburg 
genotype SORA 29 (the 12 strains typed were dif-
ferent in genotype from those found in Savo and 
Helsinki) were found in 23 people who, according 
to information in the NIDR, had been to Turkey pri-
or to falling ill. The strains isolated were susceptible 
to microlides. The median age in these cases was 51 
years, the range 10 to 70 years, and three out of five 
patients were women. Other EU Member States were 
informed of these cases through the European Cen-
tre for Disease Prevention and Control. One case of 
Salmonella Oranienburg among travellers returning 
from Turkey was found in Finland in 2009, and six 
cases in 2010. 
other salmonella clusters 
Between March and August, a strain of Salmonella 
Enteritidis phage type 14B susceptible to antibiotics 
caused 42 cases of infection all around Finland; ac-
cording to information in the NIDR, all cases were 
associated with travel to Estonia. Based on interviews 
with 9 of the patients, those who had fallen ill had 
been travelling in Tallinn, Pärnu and Tartu. They had 
no specific form of transport or itinerary in common. 
A total of 10 domestic strains of salmonella associ-
ated with this epidemic was genotyped (SENT 1). 
The strains were identical with those sent to the Na-
tional Institute for Health and Welfare by the Esto-
nian authorities from cases in Pärnu and from salmo-
nella outbreaks in Johvi and Haapsalu. The source of 
infection for these epidemics was never identified. In 
2010, 34 S. Enteritidis FT14B strains susceptible to 
all antibiotics were found, two of them from Estonia. 
In 2009, 44 similar strains were found, four of them 
from Estonia. The strains from 2009 and 2010 have 
not been genotyped. 
Between May and August, a monophasic strain of Sal-
monella Typhimurium (4,5,12:i:-), phage type 195, 
genotype STYM 58, resistant to ampicillin, strepto-
mycin, sulfonamide and tetracycline caused 22 cases 
of infection. The majority of these came from North 
Karelia Central Hospital; 18 cases were identified in 
connection with a neonatal salmonella epidemic, 10 
of them children. Also, monophasic S. Typhimurium 
was found in 6 parents and 2 hospital employees. The 
genotype is rare and had not been previously found 
in Finland. Similar monophasic Typhimurium strains 
are generally associated with intestinal infections ac-
quired in Thailand. 
Infections caused by Salmonella group E (3.10:-:1.5), 
genotype E2 were found in 14 patients between June 
and August; 11 of these were deemed to be of domestic 
origin, and 9 were found in eastern Finland. The sero-
type is extremely rare in Finland, although it did also 
cause a similar epidemic in eastern Finland in 2010.
In July and August, cases of Salmonella Typhimurium, 
phage type NST (not specific type), genotype STYM 
42 were found in 8 patients in the regions of Etelä-
Savo and Pohjois-Savo. Because these cases emerged 
individually and their total number was small, inves-
tigation of the source was not undertaken. 
campylobacteriosis in Kanta-Häme 
An elevated number of cases of campylobacteriosis 
was found around Hämeenlinna in October. The 
patients were adults of varying ages. Nine strains of 
Campylobacter jejuni were genotyped; 7 of these were 
found to be identical. The strains were compared to 
the strain of C. jejuni found at the water and waste-
water works at Loppi in October. These proved to be 
dissimilar. 
toxin-mediated food poisoning epidemic in 
savonlinna 
In September, nearly 300 patients were found to have 
contracted toxin-mediated food poisoning after shar-
ing a meal in Savonlinna. The source proved to be an 
inadequately cooled batch of lamb’s meat, where large 
quantities of Clostridium perfringens, S. aureus and L. 
monocytogenes were found. In connection with this 
epidemic, 13 patient strains of C. perfringens were 
sent to the laboratory of the National Institute for 
Health and Welfare for examination; an enterotoxin 
gene was confirmed in 11 of these. 
botulism in Helsinki 
Two members of a family in Helsinki were found to 
have contracted botulism poisoning in October; one 
of them died. Both had eaten almond-stuffed olives 
produced in Italy prior to falling ill. Botulinum toxin 
was found in the olive product, which was withdrawn 
from the market. Botulism is rare in Finland: isolated 
cases of food poisoning botulism have been recorded 
in 1999, 2006 and 2009.
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Hepatitis
The incidence of acute hepatitis A and B has remained low.• 
hepatitiS a
In 2011, the NIDR received 14 notifications of hepa-
titis A (incidence: 0.3/100,000), approximately the 
same as in 2010. Ten patients were men, and 4 were 
women. The median age was 48 years (range 4 to 
88). Cases were found in nine hospital districts, the 
largest number of them (4) in the hospital district of 
Helsinki and Uusimaa. In 7 of the cases, the infec-
tion was reported as having been acquired through 
food or water. One infection was acquired in Finland 
and 9 abroad; in 4 cases, the country of acquisition 
was not specified. Hepatitis A cases have remained 
at a low level since 2002–2003, probably because of 
high vaccination coverage among travellers and at-
risk groups. 
hepatitiS b
In 2011, the NIDR received 24 notifications of acute 
hepatitis B (0.4/100,000); three out of four patients 
were men. The majority (79%) of patients were Finn-
ish. The mode of transmission was given for 14 (42%) 
of the cases; in all of these, the infection had been 
contracted through sexual intercourse. The country 
of acquisition was reported for just over half of the 
cases (13). The majority (69%) of the infections were 
acquired abroad. 
The annual number of cases of acute hepatitis B 
peaked at just over 300 in the late 1990s. Thereaf-
ter the figure plunged sharply. Since 2005, the an-
nual number of cases has remained stable at a rather 
low level. This is probably because of high vaccina-
tion coverage among travellers and at-risk groups, 
and because of the needle and syringe exchange pro-
gramme. 
In 2011, 224 cases of chronic hepatitis B were re-
ported (4.2/100,000). The majority (82%) of pa-
tients with chronic hepatitis B were foreigners. The 
annual number of cases of chronic hepatitis has been 
decreasing since it peaked at over 400 in 1996. This 
decrease has not been as sharp as that of the acute 
cases, however. 
The NIDR criteria for classifying cases of acute hepa-
titis B have been further specified so that acute and 
chronic infections could be more reliably distin-
guished. 
hepatitiS c 
In 2011, 1,132 new hepatitis C infections were report-
ed to the NIDR, 63% of the patients being men and 
37% women. The majority (86%) of these patients 
were Finnish. The mode of transmission was intra-
venous drug use in about half of the cases and sexual 
intercourse in 11% of them. In 35% of the cases, the 
mode of transmission was not reported. The country 
of acquisition was only reported in one out of three 
cases. In 79% of the cases where the country of ac-
quisition was known, the infection was contracted in 
Finland. The largest age group, with 47% of the cases, 
was the age group of 20 to 29. The highest incidences 
were reported in the hospital districts of South Kare-
lia (33/100,000), Northern Bothnia (29/100,000) 
and Helsinki and Uusimaa (26/100,000). 
The annual number of hepatitis C infections peaked 
at 1,904 in 1997 and then decreased until 2009. In 
2010, the annual number of cases increased slightly, 
and it remained stable in 2011. 
The decrease in the annual number of cases was espe-
cially remarkable among men, being 46% from 1997 
to 2011. The annual number of cases among women 
has also decreased, but not as much as among men; 
over the same period, the decrease among women 
was 24%. Women aged 20 to 24 have shown a slight 
increase in the annual number of cases, unlike any 
other group, and in 2011 this age group had a larger 
number of cases than ever before (129).
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Figure 11. Acute hepatitis B cases involving intravenous drug use and sexually transmitted infections, 
1998–2011 (no. of cases).
Table 2. All cases of hepatitis C according to physicians´ reports, organised by means of transmission 2000–
2011, (no. of cases).
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Injecting drugs Sex
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Injecting drugs 937 826 717 637 615 629 578 468 574 516 596 600
Sex 40 42 45 46 60 62 72 68 74 70 73 86
Perinatal 6 3 3 1 11 5 5 3 11 9 10 11
Blood products 25 20 19 22 18 24 7 21 20 2 9 7
Other 31 31 28 35 31 34 37 28 34 31 38 39
Unknown 700 565 560 524 506 490 469 577 429 422 406 417
total 1739 1487 1372 1265 1241 1244 1168 1165 1142 1050 1132 1160
A very high percentage, around 80%, of intravenous 
drug users have been found to have hepatitis C anti-
bodies. It will therefore be difficult to reverse the in-
cidence trend even if the infection risks were brought 
under control. 
Changes in the annual number of cases of hepatitis C 
should be interpreted with caution, because acute and 
chronic infections are not distinguished in the statis-
tics. Surveillance is also made difficult by the fact that 
the data on the mode of transmission and country of 
acquisition are often incomplete. However, because 
hepatitis C is not transmitted easily through sexual 
contact and no community transmission has been de-
tected, the cases where the mode of transmission is 
not reported may be assumed to be mainly related to 
intravenous drug use.
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Figure 12. Hepatitis C by age group, 2000–2011 (no. of cases).
Figure 13. Incidence of Hepatitis C in Finland 2011.
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Sexually transmitted diseases
There were more cases of chlamydia than in the previous year.• 
More cases of gonorrhoea were recorded than ever before in the • 
2000s. Gonorrhoea strains continue to have a high level of resistance to 
fluoroquinolones.
The majority of HIV infections were acquired through sexual contact.• 
More than half of the HIV cases were foreigners.• 
Figure 14. Chlamydia cases in the young adult age groups, 2000–2011 (no. of cases).
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cHlamydia (cHlamydia 
tRacHomatis) 
In 2011, 13,662 cases of chlamydia were reported 
(257/100,000), which was about 800 cases more than 
in 2010; 59% of the patients were women. The high-
est incidences were reported on Åland (368/100,000) 
and in the hospital districts of Lapland (318/100,000) 
and Helsinki and Uusimaa (306/100,000). The ma-
jority of cases were in the age group of 15 to 24 for 
women (73%) and 20 to 29 for men (67%). Patients 
under the age of 20 accounted for 32% of the women 
(2,608) and 13% of the men (743). 
Ordinary chlamydia, spread through sexual contact, 
is caused by Chlamydia trachomatis immunotypes B 
and D-K. Immunotypes L1–3 cause lymphogranu-
loma venereum (LGV), known in Finland as early as 
in the 1940s under the now obsolete name neekeri-
sankkeri, literally ‘negro chancre’. LGV infections 
contracted through sexual contact between men have 
been reported in several European countries in recent 
years. Proctitis caused by LGV was found in three 
men in Finland in 2011. LGV can be typed from a 
C. trachomatis DNA-positive sample.
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Finland 129 113 100 89 133 133 112 79 90 115 123 106
Thailand 18 17 31 27 38 30 42 44 34 36 45 35
Estonia 7 3 5 2 6 1 - 2 - - 3 8
Russia 48 34 28 9 7 23 12 6 17 8 8 6
Other 32 26 18 21 21 20 25 22 24 40 33 41
Unknown 50 54 53 41 47 33 45 42 35 40 45 92
total 284 247 235 189 252 240 236 195 200 239 257 288
Table 3. Gonorrhoea infections acquired domestically and abroad, 2000–2011 (no. of cases).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Finland 54 32 25 30 22 25 21 56 57 69 36 29
Russia 80 49 22 18 16 22 18 17 26 18 26 22
Thailand 1 1 - 1 2 1 1 2 6 5 4 5
Estonia 3 2 1 6 1 6 3 4 9 3 9 4
Other 17 12 14 16 12 21 20 29 43 40 50 45
Unknown 49 63 67 62 58 68 67 79 75 67 84 74
total 204 159 129 133 111 143 130 187 216 202 209 179
Table 4. Syphilis infections acquired domestically and abroad, 2000–2011 (no. of cases).
GonoRRHoea (neisseRia 
GonoRRHoeae) 
In 2011, more cases of gonorrhoea were reported 
than in any earlier year in the 2000s: the number 
of cases was 288 (5.4/100,000). Men accounted for 
70% of the cases, and half of the cases were in the 
age group of 15 to 29. The mode of transmission was 
specified in 72% of the cases; one in three infections 
were contracted through sexual contact between men. 
The highest incidences were reported in the hospital 
district of Helsinki and Uusimaa (11.8/100,000), on 
Åland (7.3/100,000) and in the hospital district of 
Eastern Savo. The country of acquisition was speci-
fied in 68% of the cases; 46% of the infections had 
been acquired abroad. The most common country 
of origin was Thailand (35 cases) (Table 3). Neisse-
ria gonorrhoeae strains continue to have a high lev-
el of resistance to fluoroquinolones. In 2010, 57% 
of gonococcal strains were found to be resistant to 
ciprofloxacin (Finres 2010). This showed a slight im-
provement on 2009 (72%).
sypHilis (tReponema 
pallidum) 
In 2011, the number of syphilis cases reported to-
talled 179 (3.4/100,000), which was 40 fewer than 
in 2010 (209). Men accounted for 60% of the cases, 
and nearly half of the patients were in the age group 
30 to 44. The mode of transmission was given in only 
38% of the cases; of these, 45% involved sexual con-
tact between men. The incidence was highest in the 
hospital districts of Southern Karelia (12.5/100,000), 
Helsinki and Uusimaa (5.6/100,000), and Kymen-
laakso (5.0/100,000). The country of acquisition was 
specified in 59% of the cases, and of these 72% were 
acquired abroad, most often in Russia (22 cases). 
hiv and aidS 
In 2011, 176 new HIV infections were reported to 
the NIDR, 64% of the patients being men and 36% 
women. The majority of patients (56%) were foreign-
ers. The majority of HIV infections were acquired 
through sexual contact: 49% through heterosexual 
contact and 21% through male homosexual contact. 
There were only 9 cases of infection through intra-
venous injection (5%), and for 23% of the cases the 
mode of transmission was not reported.
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Figure 15. HIV cases by transmission group, 2000–2011 (no. of cases).
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The number of infections in 2011 was about the same 
as in the two previous years. By the end of the year, 
the total number of new HIV infections ever reported 
in Finland was 2,952. The number of HIV findings 
has increased due to a growth in infections transmit-
ted through heterosexual and male homosexual con-
tact. By contrast, transmission through intravenous 
drug use has remained at a low level. 
The number of infections from heterosexual contact 
in 2011 was 87, accounting for nearly half of all new 
cases. About three out of five patients (49) were for-
eigners. The foreigners had contracted the infection 
abroad (with one exception), usually in their home 
country. A significant number of Finnish patients, 
two out of three, had also contracted the infection 
abroad (excluding the cases where the country of ac-
quisition is not known). The number of infections 
from heterosexual contact has been steadily growing 
throughout the history of the epidemic, among both 
foreigners and Finns. 
The number of infections from homosexual contact 
between men in 2011 was 36. The majority (86%) 
of these patients were Finnish. About half of the 
Finns had contracted the infection in Finland and 
half abroad (excluding the cases where the country 
of acquisition is not known). Infections from homo-
sexual contact between men began to increase again 
at the beginning of the 2000s and peaked at 72 new 
infections in 2007. Since then, the annual number of 
new infections has been about 40. The incidence of 
HIV in this group is significantly higher than in the 
general population.
There were 9 cases of HIV associated with intrave-
nous drug use in 2011, 2 Finns and 7 foreigners. The 
foreigners had contracted the infection abroad. Ef-
fective preventive measures have kept infections from 
intravenous drug use at a low level following the HIV 
epidemic at the turn of the millennium. 
One case of mother-child infection was reported in 
2011; this child had been born abroad. A total of 
14 mother-child HIV infections have been found in 
Finland in the 2000s, all but one of them of foreign 
origin. Mother-child transmission can be effectively 
prevented with medication during pregnancy. 
In 2011, there were 3 reported cases of HIV infection 
possibly caused by a blood transfusion. The transfu-
sion had been performed abroad. There have been no 
reported cases of infection through blood products 
in Finland since HIV testing of donated blood began 
in 1985. 
In 2011, the mode of transmission was not report-
ed in 23% of the cases. In nearly 90% of these ‘not 
known’ cases the patient was a foreigner, and the 
principal reason for the lack of data was the absence 
of a physician’s report. A physician’s report was lack-
ing in 23% of the cases involving foreign patients and 
in 3% of the cases involving Finnish patients. 
A record number of HIV infections were found in 
foreigners in Finland in 2011 (99). For the first time 
ever, foreigners outnumbered Finns among new HIV 
cases. The foreign patients were of more than 30 na-
tionalities, mostly from countries of origin where 
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the incidence of HIV is high. The principal mode of 
transmission was a heterosexual contact.
In 2011, 24 cases of AIDS were diagnosed, 17 of 
them in Finns and 7 in foreigners. AIDS was the 
cause of death in 5 cases. There have been no signifi-
cant changes in the number of AIDS cases and AIDS-
induced deaths after the mid-1990s, when efficient 
combination medicines were introduced. By the end 
of 2011, 299 persons in all had died from AIDS in 
Finland. 
As in early years, the percentage of late detection of 
infections was high. In 2011, infection was detect-
ed late in about half of the cases (CD4 < 350). The 
late detection percentage was about the same among 
both Finns and foreigners. Late diagnosis weakens 
the treatment prognosis and increases the possibility 
of further infections. Changes in primary resistance 
were found in 4% of the HIV virus strain samples in 
2011, which by European standards is low.
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Antimicrobial resistance
There were more MRSA blood culture findings than in the previous year.• 
VRE findings increased in northern Finland.• 
There were more ESBL blood culture findings than in 2010.• 
mRSa
In 2011, 1,327 cases of methicillin-resistant Staphy-
lococcus aureus (MRSA) were reported to the NIDR, 
about the same number as in the year before (2010: 
1,267). Of these, 25% (2009−2010: 22−24%), were 
diagnosed only from samples taken from the nose or 
the nostrils. There were more MRSA blood culture 
findings than in the previous year (2011: 42; 2010: 
26). Of these MRSA blood culture findings, 22 (52%) 
were in the Pirkanmaa hospital district (4.5/100,000) 
and 8 (19%) in the hospital district of Helsinki and 
Uusimaa (0.5/100,000). The other hospital districts 
reported zero to three cases each, totalling 12. Most 
(30 out of 42) of the invasive cases occurred in pa-
tients older than 65, and 2 in children. As earlier, the 
hospital districts of Pirkanmaa and of Helsinki and 
Uusimaa reported the highest total figures. The in-
cidence per 100,000 inhabitants was highest in the 
hospital districts of Pirkanmaa, Western Bothnia and 
Northern Karelia. The percentage of findings in pa-
tients aged over 75 was 44%, similar to the figure 
for the previous year. The number of MRSA cases in 
children remained stable (94). 
An MRSA strain isolated from the blood was typed 
in more than 1,350 individuals. There were 160 dif-
ferent spa types in the MRSA strains (2010: 165). 
The most common spa types were the same as in the 
previous year: t067 28% (2010: 28%), t172 18% 
(14%), t008 8% (9%), t002 4% (4%) and t032 3% 
(3%). 
t067 was found in five hospital districts, most com-
monly in Pirkanmaa, and t172 was found in 18 hos-
pital districts. 
As in previous years, the t008 and t002 strains were 
also typed using pulse field gel electrophoresis (PFGE). 
Both were divided into several PFGE types. More than 
a third (37%) of the t008 strains were of PFGE type 
FIN-25, an internationally known strain of MRSA 
originating in outpatient care (USA 300), and one out 
of five (18%) were of PFGE type FIN-7. 
Local clusters (MRSA strain isolated in more than 
10 patients) also occurred in the hospital districts of 
Kymenlaakso (t223), Northern Karelia (t267, t034, 
t721), Pirkanmaa (t1012) and Western Bothnia 
(t2099). 
The most common spa type among patients over 75 
was t067 (37%; 2010: 39%). The most common spa 
types among children under the age of 16 were t172 
(19%), t223 (11%) and t002 (9%), mostly of PFGE 
type FIN-16). In 2010 too, the most common spa 
types among children were t223 (18%) and t172 
(9%), along with t008 (12%). 
An MRSA strain isolated from the blood was typed 
in 31 individuals. The two most common spa types 
were also the most commonly found in blood cul-
tures. Spa type t067 was found in 12 samples and 
t172 in 8, the rest (11 out of 31) representing 10 dif-
ferent spa types. 
vRe
In 2011, the number of vancomycin-resistant ente-
rococcus (VRE) findings reported to the NIDR in-
creased on the previous year (2011: 128; 2010: 92). 
Most of the findings were reported by the hospital 
districts of Western Bothnia, Northern Bothnia and 
Lapland (100 out of 128); the majority of the pa-
tients were men (76 out of 128); and the largest age 
group was those over 75 (58 out of 128). In other 
hospital districts, the number of findings varied from 
0 to 9. Four of the findings were from blood. 
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Figure 16a and 16b. MRSA cases by hospital district, 2000–2011 (no. of cases).
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VRE findings were typed in 123 individuals. All find-
ings except for two were of the E. faecium species, and 
most of these were of the vanB type (116 out of 121). 
PFGE revealed that a new epidemic strain, VRE X, 
was spreading in the hospital districts of Western 
Bothnia, Northern Bothnia and Lapland, and this 
was eventually the most common type of strain in 
2011 (85 out of 123 cases). VRE XI was the cause of 
9 cases in 2011, of which were in the Northern Both-
nia hospital district. Both epidemic strains were also 
identified using multilocus sequence typing (MLST); 
their sequence types – ST117 (VRE X) and ST17 
(VRE XI) – belong to the E. faecium CC-17 clone, 
which is internationally known as spreading in hos-
pitals. Only two cases of the VRE VIII strain, which 
had spread in the hospital district of Southwest Fin-
land in 2010, were found in 2011. The remaining 28 
out of 123 cases involved isolated unique findings (26 
out of 123) or findings of VRE XII (2 out of 123). 
eSbl
Since the beginning of 2008, third-generation 
Escherichia coli and Klebsiella pneumoniae exhibiting 
reduced susceptibility or resistance to cephalosporin 
(I for intermediate and R for resistant, respectively) 
have been reported to the NIDR. The majority of 
these bacteria are enzyme-producing ESBL strains 
and extended-spectrum cephalosporins that split 
penicillin. 
In 2011, the majority of ESBL findings (3,119) were 
E. coli (2010: 2,528), with a small number (244) of 
Klebsiella pneumoniae (2010: 184). ESBL in E. coli 
was diagnosed in all age groups – almost 75% in 
women and over half in patients aged 65 years or 
more. The majority of diagnoses (72%, 2,238 out of 
3,119) were made from urine. The largest number of 
cases was found in the hospital district of Helsinki 
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all mRsa  
findings
s. aureus blood culture  
findings
mRsa blood culture findings and the 
methicillin resistance of  s. aureus (%)
1995 89 627 2 (0,3)
1996 110 667 0 (0,0)
1997 121 747 4 (0,5)
1998 190 719 5 (0,7)
1999 212 813 8 (1,0)
2000 266 850 4 (0,5)
2001 340 887 4 (0,5)
2002 600 989 9 (0,9)
2003 859 981 7 (0,7)
2004 1478 1059 30 (2,8)
2005 1381 1013 27 (2,7)
2006 1330 1239 37 (3,0)
2007 1297 1179 32 (2,7)
2008 1772 1261 40 (3,2)
2009 1267 1288 30 (2,3)
2010 1267 1370 26 (1,9)
2011 1327 1487 42 (2,8)
total 13906 17176 307 (1,8)
Table 5. MRSA-findings and their percentage of S. aureus blood culture findings, 1995–2011 (no. of cases and %).
cases reported to  
the nidR
studied  
strains
erythromycin 
(R) (%)
penicillin (i+R) 
(%)
multidrug  
resistance (%)
1998 561 84 3,6 0 0
1999 568 471 5,9 7,2 0
2000 601 439 8,0 3,7 1,4
2001 658 360 18,8 7,5 5,0
2002 599 594 16,3 8,0 3,7
2003 721 739 21,9 12,7 5,7
2004 748 748 20,5 9,6 3,7
2005 735 731 20,5 9,6 4,4
2006 741 760 27,9 16,4 5,4
2007 788 794 23,2 14,4 3,5
2008 924 930 24,5 17,7 3,4
2009 854 848 28,4 19,9 4,7
2010 827 819 28,6 23,4 1,7
2011 779 780 26,8 21,9 2,8
I – reduced susceptibility: R – resistant; Multidrug resistance – strains simultaneously resistant to penicillin (I+R),  
erythromycin (R) and tetracycline (R)
Table 6. Antimicrobial resistance of Streptococcus pneumoniae in blood and cerebrospinal fluid culture find-
ings, 1998–2011 (no. of cases and %).
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Figure 17. Streptococcus pneumoniae findings in blood and cerebrospinal fluid culture by serotype, 2011 (no. 
of cases).
and Uusimaa (991, 65/100,000), but the incidence 
was highest in the Central Finland and Western Both-
nia hospital districts (90 and 89/100,000, respective-
ly). There were considerably more ESBL findings in 
blood than in 2010 (150 vs. 112) (ESBL percentage 
of E. coli blood culture findings was 4.3%, or 150 out 
of 3,473,  as opposed to 3.5% in 2010). The major-
ity of the findings were made in the hospital district 
of Helsinki and Uusimaa. However, the incidence in 
blood findings was highest in the Lapland, Central 
Finland and Northern Karelia hospital districts. 
Over half of the ESBL cases reported that involved 
K. pneumoniae were also diagnosed in patients aged 
65 years or over, but the percentage of women was 
smaller than with E. coli, being 62%. The majority 
of diagnoses (62%, 151 out of 244) were made from 
urine. The largest number of cases was recorded in 
the hospital districts of Helsinki and Uusimaa (66) 
and Northern Bothnia (52), while the incidence was 
highest in the Western Bothnia and Northern Both-
nia hospital districts. There were 16 blood findings 
(2010: 16) (percentage of ESBL in K. pneumoniae 
blood cultures was 3.6%, or 16 out of 449, as op-
posed to 3.2% in 2010). 
strains producing esbl and carbapenemase 
In 2011, genes encoding extended-spectrum beta-
lactamases (ESBL) were specified in 203 bacterial 
strains. The strains had been collected for epidemic 
control or confirmation of third-generation cepha-
losporin-resistance. The figure includes 133 E. coli 
and 34 K. pneumoniae strains. Out of the E. coli and 
K. pneumoniae strains isolated in 2011, 61% and 
42%, respectively, had an extended-spectrum beta-
lactamase of the CTX-M group. 
In 2011, carbapenemase-coding genes in 149 spe-
cies of the Enterobacteriaceae genus were investigated. 
These strains had been sent for carbapenemase gene 
studies because of their reduced susceptibility to car-
bapenems. Of the strains examined, 12 had a car-
bapenemase gene: NMC-A, OXA-48/181, NDM or 
VIM. Carbapenemase genes were found in strains of 
E. coli, K. pneumoniae and Enterobacter cloacae. The 
sequence types of these strains varied. 
The change from 2010 was that OXA-48/181 was 
now the most common finding, being found in 
strains of both E. coli and K. pneumoniae. Seven of 
the patients had had contact with a hospital abroad 
or had been travelling abroad. Foreign contact could 
not be established for all patients, however. 
In addition to the species in the genus Enterobacte-
riaceae, 152 strains of Acinetobacter baumannii and 
Pseudomonas aeruginosa were examined for carbapen-
emase genes because of their reduced susceptibility to 
carbapenems. The PCR test found a positive result 
in 14% of the cases. A. baumannii had genes of the 
OXA group which are typical for it (OXA-51, OXA-
58, OXA-24 and OXA-23). P. aeruginosa strains were 
found to have metallo-beta-lactamase genes VIM and 
IMP. Patients from whom a strain of P. aeruginosa 
with the VIM carbapenemase gene was isolated had 
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had contact with a hospital abroad. No similar link 
to hospitals abroad could be established for strains 
with the IMP gene. This means that strains with 
IMP metallo-beta-lactamase may already be present 
in Finnish hospitals. There was no change compared 
with 2010.
A major percentage of bacterial strains with carbap-
enemase is thus of foreign origin, but more strains of 
Finnish origin were found than before. However, no 
local epidemics have been noted as yet. 
invaSive pneumococcal 
disease (stReptococcus 
pneumoniae) 
In 2011, 779 cases (14/100,000) of invasive pneumo-
coccal disease were reported (2010: 827, 15/100,000). 
As in previous years, the incidence was higher among 
men than among women (17 vs. 12/100,000). Re-
gional variation was significant (7–26/100,000), 
which may be due to differences in how actively sam-
ples were taken. 
In 2011, 796 strains of invasive pneumococcus were 
serotyped. Only small changes in the serotype distri-
bution compared with 2010 were found; the most 
common serotype is still 14, which accounted for 
18% of all strains serotyped. 
In 2011, the antimicrobial susceptibility of 780 pneu-
mococcal strains isolated from invasive infections was 
analysed. Strains with reduced susceptibility to peni-
cillin (MIC > 0.06 mg/L) accounted for 22% of the 
strains, and strains completely resistant to penicillin 
(MIC > 2 mg/L) accounted for 0.3%. The propor-
tion of macrolide-resistant strains decreased slightly; 
27% of invasive pneumococcal strains were resist-
ant to erythromycin. Multiresistant strains (PEN 
IR-ERY R-TET R) accounted for 2.8% of the strains. 
No strains resistant to levofloxacin (MIC > 2 mg/L) 
or ceftriaxon (MIC > 2 mg/L) were found in 2011. 
What is important to note is that the 2011 report 
follows the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) breakpoints rather 
than the US Clinical and Laboratory Standards Insti-
tute (CLSI) breakpoints followed up to and includ-
ing the 2010 report. Despite this, it may be noted the 
changes in the susceptibility of invasive pneumococ-
cus strains when compared with 2010 findings were 
minor. The decrease in the number of penicillin-re-
sistant strains was due to the breakpoint adjustment.
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Tuberculosis
As previously, the majority of cases of tuberculosis are found in elderly patients • 
who contracted the infection in their youth.
One out of four cases of tuberculosis are found among immigrants.• 
The incidence of tuberculosis among children under the age of 5 has not • 
increased since 2006, when the BCG vaccine was restricted to at-risk groups.
tubeRculoSiS 
(mycobacteRium 
tubeRculosis)
tuberculosis surveillance 
Between 1995 and 2006, the registered tuberculo-
sis cases included all cases confirmed by culture, as 
reported by the laboratories. In addition, cases re-
ported by a physician were included, but only if the 
diagnosis was based on histology or a case of pulmo-
nary tuberculosis was confirmed by positive sputum 
staining for tuberculosis bacilli. Since 2007, Finland 
has followed the case definition of the European Un-
ion’s infectious disease surveillance for tuberculosis: 
in addition to cases fulfilling the criteria mentioned 
above, the statistics also include cases in which a phy-
sician suspected tuberculosis on the basis of clinical 
evidence and decided to give full tuberculosis treat-
ment even though the infection was not confirmed 
by microbiological tests or histology. The new criteria 
for compiling statistics did not affect the number of 
cases confirmed by laboratory tests or histology. 
incidence of tuberculosis 2011 
In 2011, there were 326 (6.1/100,000) tubercu-
losis cases, which is one more than in 2010 (325, 
6.0/100,000). Of the cases, 236 (72%) were pul-
monary tuberculosis, and 86 (36%) of them were 
sputum staining-positive. There were 251 cases of 
tuberculosis confirmed by culture, seven fewer than 
in 2010 (258). According to physicians’ reports, 14 
patients (4%) had a previous history of tuberculosis 
diagnosed after 1950, when anti-tuberculosis medi-
cation became available. 
The increase in the overall number of tuberculo-
sis cases in Finland in 2007 and 2008 compared to 
2006 can be explained by the introduction in 2007 
of the broader EU definition of tuberculosis cases. 
The annual numbers of cases confirmed by culture 
are comparable throughout the surveillance period. 
The number of cases of pulmonary tuberculosis con-
firmed by culture and with positive sputum staining 
has remained stable since 2007 except for a spike in 
cases among foreigners in 2009. 
The age distribution of tuberculosis cases was as fol-
lows: under 15 years, 11 cases (3%); 15 to 29, 49 
cases (15%); 30 to 44, 35 cases (11%); 45 to 59, 43 
cases (13%); 60 to 74, 90 cases (28%); and 75 or 
more, 98 cases (30%). Nearly 60% of all cases were 
over 60 years of age, and most of them were born in 
Finland; these cases involved a reactivation of a la-
tent infection contracted decades ago. No increasing 
trend has been found in children aged under 5 after 
the change to the vaccination programme in 2006. 
In 2011, there were 80 foreign cases (25%), i.e. either 
born abroad or in the absence of country of birth, 
citizenship other than Finnish. The age distribution 
of these was as follows: under 15 years, 4 cases (5%); 
15 to 44, 64 cases (80%); 45 to 59, 5 cases (6%); and 
over 60, 7 cases (9%). Among these there were 49 
cases (61%) of pulmonary tuberculosis and 31 cases 
(39%) of other forms of tuberculosis. Information on 
the patient’s country of birth or citizenship was miss-
ing in 6 cases (2%). 
In 6 (2%) of the tuberculosis cases reported in 2011, 
the patient also had an HIV infection. Three of these 
were new HIV infections reported in 2011, and three 
had been reported earlier. Four of the cases were 
foreign in origin.
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pulmonary tuberculosis other  
tuberculosis
all cases
cases cases  
/100,000
cases with 
positive  
sputum 
smear
cases with 
positive  
sputum 
smear 
/100,000
cases cases  
/100,000
cases cases  
/100,000
culture-
confirmed 
cases
propor-
tion of 
culture-
confirmed 
cases (%)
1995 436 8,6 241 4,7 217 4,3 653 12,8 475 72,7
1996 442 8,6 232 4,5 193 3,8 635 12,4 513 80,8
1997 360 7,9 185 3,6 197 3,8 557 10,9 442 79,4
1998 397 7,7 203 3,9 213 4,1 610 11,9 494 81
1999 405 7,8 185 3,6 188 3,6 593 11,5 510 86
2000 376 7,3 227 4,4 171 3,3 547 10,6 460 84,1
2001 312 6 150 2,9 181 3,5 493 9,5 411 83,4
2002 299 5,8 136 2,6 175 3,4 474 9,1 392 82,7
2003 290 5,6 144 2,8 122 2,3 412 7,9 348 84,5
2004 233 4,5 128 2,5 103 2 336 6,4 291 86,6
2005 269 5,1 136 2,6 100 1,9 369 7 321 87
2006 212 4,0 101 1,9 83 1,6 295 5,6 270 91,5
2007 235 4,5 93 1,8 111 2,1 346 6,6 250 72,3
2008 222 4,2 109 2,1 124 2,3 346 6,5 247 71,4
2009 295 5,5 96 1,8 116 2,2 411 7,7 303 73,7
2010 242 4,5 88 1,6 83 1,5 325 6,0 258 79
2011 236 4,4 86 1,6 90 1,7 326 6,1 251 77
Table 7. Incidence of tuberculosis and percentage of culture-confirmed cases in Finland, 1995–2011 (no. of 
cases and %).
pulmonary tuberculosis other tuberculosis all cases
cases in  
foreigners
proportion 
of foreigners 
(%)
cases in  
foreigners
proportion 
of foreigners 
(%)
cases in  
foreigners
proportion 
of foreigners 
(%)
1995 25 5,7 13 6 38 5,8
1996 17 3,8 24 12,4 41 6,5
1997 23 6,4 23 11,7 46 8,3
1998 26 6,5 31 14,6 57 9,3
1999 25 6,2 21 11,2 46 7,8
2000 29 7,7 16 9,4 45 8,2
2001 34 10,9 28 15,5 62 12,6
2002 23 7,7 24 13,7 47 9,9
2003 36 12,4 13 10,7 49 11,9
2004 22 9,4 20 19,4 42 12,5
2005 28 10,4 24 24 52 14,1
2006 30 14,2 22 26,5 52 17,6
2007 45 19,1 28 25,2 73 21,1
2008 31 14 22 17,7 53 15,3
2009 81 27,4 43 37,1 124 30,1
2010 72 30 32 39 104 32
2011 49 20,8 31 34,4 80 24,5
Table 8. Cases of tuberculosis in foreigners, 1995–2011 (no. of cases and %).
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2007 2008 2009 2010
Cases under surveillance 200 191 241 197
tReatment outcome
favourable 144 (72 %) 140 (73 %) 167 (69 %) 143 (73 %)
Cured 85 89 84 90
Treatment completed 59 51 83 53
non-favourable 41 (21 %) 37 (19 %) 44 (18 %) 21 (11 %)
Deceased 38 (19 %) 33 (17 %) 41 (17 %) 17 (9 %)
Treatment failure 1 1 0 0
Interrupted treatment 2 3 3 4
missing 15 (7 %) 14 (7 %) 30 (12 %) 33 (17 %)
Transfer 2 2 13 5
Treatment continues at 12 months 7 9 9 9
Notified, as not known 1 3 2 2
Notification missing 5 0 6 17
Table 9. Results of  treatment outcomes in microbiologically confirmed pulmonary tuberculosis, 2007–2010 
(no. of cases and %).
tuberculosis typing findings 2011 
All new M. tuberculosis strains were genotyped in 2011 
using the internationally standardized spoligotyping 
and MIRU-VNTR methods. The use of genotyping 
in the investigation of contacts was clarified in a guide 
published in 2011 titled “Suositus tuberkuloosin kon-
taktiselvityksen toteuttamiseksi”[Recommendation 
for conducting investigations of contacts for tuber-
culosis]. 
Of the typed strains, 19% presented in clusters of 2–4 
strains. Spoligotype SIT53 is very common in Fin-
land and can be separated into several clusters using 
the MIRU-VNTR method. Three new SIT53 clus-
ters were found in 2011 in addition to those found 
earlier. Three new cases emerged in the SIT53 cluster 
that had spread among socially marginalized people 
in the Tampere region. The total number of strains 
genotyped in this cluster at the National Institute for 
Health and Welfare is 24. 
Five new cases were added to the SIT914 cluster as-
sociated with hospital environments, bringing the to-
tal to 16 cases. Three new cases were added to the 
SIT40 cluster in Tammisaari and two new cases to 
the Jazz cluster (SIT42). Also, two new SIT42 clus-
ters were found using the MIRU-VNTR method. 
One new strain each was added to the already known 
clusters in Pirkkala (SIT49), in Satakunta (SIT262) 
and among young immigrants (F404). 
One case of laboratory contamination was found by 
typing. Also two cases caused by species of tuberculo-
sis bacteria belonging to the M. tuberculosis complex 
that are rare in Finland (M. bovis and M. africanum) 
were found. 
tuberculosis strain susceptibility in 2011 
The susceptibility of Mycobacterium tuberculosis strains 
in Finland remains good. Of all cultured strains, 94% 
had full susceptibility; in five cases, the pathogen was 
a multiresistant strain (MDR), and two of these were 
found in cases of Finnish origin. 
tuberculosis outcome surveillance in 2007–
2010 
Table 9 shows the distribution of treatment outcomes 
between 2007 and 2010. The surveillance covers cases 
of pulmonary tuberculosis confirmed by culture, nu-
cleic acid detection or mycobacterial staining. Cases 
where the pathogen is an MDR strain are reported 
separately and are not included in Table 9. The out-
come evaluation is performed 12 months after the 
case is registered. Some of the outcome evaluation 
forms for 2010 have not yet been returned, because 
of which the data is not as comprehensive as in previ-
ous years. 
The preliminary figures for 2010 show that the out-
come was good in 73% of cases, roughly the same 
figure as in previous years. It falls clearly short of the 
international target set by the WHO at 85% but is 
on a par with the average for EU Member States. 
The mortality rate (before starting treatment or dur-
ing treatment) was 9% in 2010, clearly lower than in 
previous surveillance years.
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Other infections
There was a considerably larger number of cases of measles than in previous years. • 
Most of these were cases imported from Europe.
There were more cases of tick-borne encephalitis than ever before.• 
Another record high was noted in borreliosis incidence.• 
Most of the year’s malaria infections were contracted in Africa.• 
Dengue fever cases have been on the increase in recent years.• 
The number of adult blood cultures continued to grow.• 
HaemopHilus (HaemopHilus 
influenzae) 
In 2011, there were 66 reported infections caused by 
the Haemophilus influenzae bacterium, diagnosed in 
blood or CSF, more than half as many again as in 
the previous year. The majority of these (88%) were 
caused by unencapsulated strains of Haemophilus in-
fluenzae. Serotype b caused an illness in two adults 
and two children, aged 4 and 11. The adults were in 
an age group for which the Hib vaccination was not 
yet included in the vaccination programme in their 
childhood. The younger of the two children had not 
received the Hib vaccine at all, and the older one had 
not had the Hib vaccination booster shot that should 
have been given in the second year of life. Children 
born in 1985 or later have received the Hib vaccine at 
the child care clinic. Since the beginning of 2005, un-
der the revised vaccination programme, the Hib vac-
cination is administered as a component of a combi-
nation vaccine at 3, 5, and 12 months. The efficiency 
of the vaccination is monitored, and vaccination data 
are investigated for all children diagnosed with Hib. 
meninGococcus (neisseRia 
meninGitidis) 
In 2011, the number of meningococcus infections 
detected in blood or CSF totalled 34 (0.63/100,000), 
which is about the same as in the previous three years. 
The number and percentage of group Y cases de-
creased to about half of what they were in the previ-
ous year (Table 10). 
19 of the cases (56%) were caused by group B menin-
gococcus and 7 cases (21%) by group Y. There were 
6 cases (18%) caused by group C. The age distribu-
tion of the cases was much the same as in previous 
years: 5 patients aged 0 to 4, 2 patients aged 5 to 
14, 7 patients aged 15 to 19 and 20 patients aged 20 
or over. The incidence of the type B:P1.7-2,4:F1-5 
strain that has been causing outbreak clusters in Ger-
many, was higher than in the previous year (2011: 10 
cases; 2010: 3 cases). The group Y strains belonged 
to four different types. No temporal or local clusters 
were detected. 
In isolated cases of meningococcus, all persons in close 
contact with the patient except for health care person-
nel should be given prophylactic medication and also 
a vaccination if infection from that strain can be pre-
vented by vaccination. Finland has vaccines against 
meningococcus serogroups A, C, W135 and Y. 
mmR diseases (measles, 
mumps, Rubella) 
There was a considerably larger number of cases of 
measles in 2011 than in previous years. The number 
of cases was 27, most of them in the Helsinki Metro-
politan Area. The disease was imported from Europe, 
particularly France, where the disease has had a high 
incidence since 2010. However, the majority of the 
infections in 2011 were contracted in Finland as a 
result of someone arriving from abroad with the dis-
ease, e.g. in the family or through other close contact; 
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Group a Group b Group c Group y Group W135 unknown total
2000 0 30 11 2 3 2 48
2001 0 34 9 4 1 3 51
2002 0 36 6 4 1 2 49
2003 0 28 5 6 0 2 41
2004 0 29 5 4 2 4 44
2005 0 33 1 3 0 3 40
2006 0 38 5 1 0 1 45
2007 0 29 8 5 0 1 43
2008 0 19 8 2 0 0 29
2009 0 24 3 5 0 1 33
2010 0 14 4 13 1 3 35
2011 0 19 6 7 1 1 34
Table 10. Meningococcal infections by serogroup, 2000–2011 (no. of cases).
however, the source of infection could not be defi-
nitely established in all cases. Of those who contract-
ed measles, 8 were under the age of 4, 3 were teen-
agers and the rest were adults. The majority of them 
had not been vaccinated, either because of their age 
or because of other reasons. However, a few patients 
who had received one or two doses of the MMR vac-
cine also contracted measles. Unvaccinated patients 
presented with typical measles symptoms, but vacci-
nated patients generally presented with very mild or 
atypical symptoms.
The measles viruses that caused the isolated cases ear-
ly in the year were of the subtypes G3 and D8, but all 
the other typed viruses were of genotype D4, which 
was very common in Europe in 2010 and 2011. Lab-
oratory tests on the cases of measles indicated that 
some of the cases would not have been detected if 
only one serum sample had been tested. To confirm a 
diagnosis of measles, it is important to take not only 
a serum sample but also saliva sample, throat swab 
and urine samples for PCR testing and virus charac-
terization. 
Two unvaccinated adults contracted mumps in 2011; 
the source of the infections is not known. 
Rubella was imported to Finland from Vietnam in 
2011. Two unvaccinated adults had contracted the 
disease during a trip to Vietnam. Also, one case of 
congenital rubella syndrome (CRS) was found in 
2011. The mother had had rubella while pregnant in 
Vietnam before moving to Finland. It had been 25 
years since the previous CRS diagnosis recorded in 
Finland.
puumala viRuS 
In 2011, 1,833 cases of Puumala virus were reported 
(34/100,000), some 400 cases more than in 2010 but 
clearly fewer than in the record year 2008 (more than 
3,200). The number of cases varies, depending on the 
virus reservoir, i.e. the size of the bank vole popula-
tion. The variation usually follows a three-year cycle 
such that two abundant years are followed by a qui-
eter year. Earlier peaks in epidemic nepropathy oc-
curred in 2002, 2005 and 2008, so a higher incidence 
was expected in the previous year. The patients’ age 
and gender distribution was the same as before. Of 
the patients, 59% were men, and most patients were 
of working age. There were 97 (5%) under 20 years of 
age. This time, the incidence was highest in the East-
ern Savo hospital district (112/100,000 population) 
and the Southern Savo hospital district (109/100,000 
population). 
ticK-boRne encepHalitis (tbe) 
In 2011, 62 TBE antibody findings were reported to 
the NIDR, more than in any year before (2000–2010: 
16 to 44 per year), however only 43 patients present-
ed with symptoms consistent with the disease. 
Findings positive for TBE were found between May 
and November, peaking in August. The patients’ age 
range was 6 to 80. The patients included 8 people 
from Åland (all unvaccinated), 33 from elsewhere in 
Finland, one foreigner who contracted the disease 
on Åland and one Swedish national who contracted 
the disease in Sweden. In order to identify the place 
of acquisition, the National Institute for Health and 
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Welfare interviewed patients who had been diag-
nosed with TBE in 2011 and/or studied their patient 
records. The distribution of places of acquisition was 
as follows: 13 (30%) in the Turku archipelago, 12 
(28%) on Åland, 2 in Maalahti, 2 in the Kotka ar-
chipelago, 2 in the Sipoo archipelago, 2 on the shores 
around Helsinki, 1 in Lappeenranta, 1 in Länsi-Uusi-
maa, 1 in Simo and 1 near Outokumpu. Two Finn-
ish nationals contracted the disease in Estonia, one in 
Russia and one in Sweden. In one case, the location 
of acquisition remained unclear.
If a patient falls ill with meningitis or encephalitis 
between May and October even though he or she 
has not noticed a tick bite, TBE should be suspected, 
especially if this happens in known high-risk areas. 
Because new endemic TBE regions may continue to 
emerge, it is a good idea to consider the possibility 
of TBE infection even beyond currently known risk 
areas. 
tulaRemia (fRancisella 
tulaRensis) 
In 2011, 75 laboratory-confirmed cases of tularemia 
were reported (1.4/100,000), the highest number of 
cases (35) being reported in the Northern Bothnia 
hospital district as in the previous year. The incidence 
was highest in the Northern Bothnia (8.8/100,000), 
Southern Bothnia (5.5/100,000) and Central Both-
nia (5.3/100,000) hospital districts. The age and gen-
der distribution of the cases were similar to what they 
had been in earlier years. The patients were 5 to 91 
years old (median: 49 years), and 63% of them were 
women. As is typical, the majority of the cases were 
diagnosed in August and September. 
Tularemia is mainly transmitted by insect stings, 
which explains why the incidence of the disease 
peaks in late summer. In addition, tularemia bacteria 
Figure 18. Cases of  Puumala virus by hospital district, 2011 (no. of cases per 100,000 population).
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Figure 19. Cases of  Borreliosis by hospital district, 2011 (no. of cases per 100,000 population).
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are easily transmitted by inhalation in aerosol form 
or through direct contact with an infected animal. 
The bacteria may also be transmitted through con-
taminated water or food. The incubation period for 
the disease is 3 to 5 days on average, and its clinical 
picture depends on the mode of transmission. The 
annual incidence of tularemia varies greatly (0.5 to 
18/100,000 since 1995), and the epidemics that oc-
cur with a cycle of a few years tend to be local. 
poGosta disease (sindbis 
viRus) 
In 2011, 63 cases were reported. The incidence was 
highest in the Southern Savo and Northern Karelia 
hospital districts, being 4.6/100,000 in both. The pa-
tients were 19 to 75 years old (median: 49 years), and 
35 of them (56%) were women. The majority of the 
cases, 51 (81%), were diagnosed between July and 
September.
Sindbis virus is assumed to be transmitted mainly by 
insect stings. Temperatures in early summer and rain-
fall and snowfall in the previous winter significantly 
affect incidence. Waterway regulation, other local 
ecological and socioeconomic factors together with 
cyclical variation in available animal reservoirs (for-
est game birds) may also play a role. Cases of Pogosta 
disease tend to cluster in the period from late July to 
September. After the incubation period, which is less 
than one week, the disease causes a fever which may 
be associated with a rash and joint symptoms which 
may be long-term and last several years. 
Pogosta disease has followed a regular seven-year cy-
cle since 1974 except for 2009. The epidemic peaked 
in 1981, 1995 and 2002; in 2009, however, only 106 
cases were found (2/100,000).
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continent country cases
Asia India 3
Indonesia 1
Cambodia 1
Malaysia 1
Pakistan 1
Total 7
Africa Gambia 1
Ghana 2
Cameroon 5
Kenya 3
Congo 1
Liberia 1
Mozambique 1
Nigeria 5
Ivory Coast 1
Sierra Leone 3
Sudan 1
Tanzania 2
Total 26
America Brazil 1
Total 1
total 34
Table 11. Malaria cases in Finland in 2011 by country 
of acquisition.
boRRelia (lyme disease) 
In 2011, the number of borrelia cases reported was 
1,662, more than ever before. The previous record 
was 1,467 in 2009, the number of cases in 2010 be-
ing 1,442. The incidence in the whole country was 
31/100,000 on average, but once again there was sig-
nificant regional variation. As before, the incidence 
was highest on Åland (1,746/100,000), accounting 
for 30% of all diagnosed borrelia infections in Fin-
land, 489 cases. As in previous years, the incidence of 
borrelia was highest in the autumn, from August to 
November. The majority of the patients (74%) were 
aged over 45; 53% of the patients were women. 
RabieS 
Doctors are required to report cases where risk assess-
ment has led to the start of rabies vaccination treat-
ment after exposure. In 2011, 57 suspected cases of 
rabies were reported to the NIDR. There were 35 pa-
tients who had been exposed during a trip abroad, 11 
of them in Thailand. Some had been exposed in In-
donesia, India, Russia and Lithuania, and there were 
some additional isolated cases. In most of the cases 
contracted abroad, exposure consisted of dog bites. 
Exposure in Finland was reported in 22 cases, half of 
them associated with bat contacts. Three cases of ex-
posure to rabies vaccine bait were reported. 
malaRia 
Malaria was diagnosed in 34 patients in Finland in 
2011. There were 23 cases of Plasmodium falciparum, 
8 cases of P. vivax, and 3 cases of P. ovale. The ma-
jority of the infections were contracted in Africa (26 
cases, or 76%), 18 of them in western Africa. There 
were 4 infections acquired on the Indian subconti-
nent, 3 in South-East Asia and 1 in South America. 
Of the malaria patients, 7 were native Finns who had 
taken a trip of less than six months to a malaria re-
gion, and 2 were Finns residing in a malaria region. 
A further 17 (50%) were immigrants from a malaria 
region who had returned to visit their home country; 
4 were immigrants who had fallen ill immediately af-
ter arriving in Finland. Four patients were visitors to 
Finland. The number of malaria cases and the risk 
groups remained approximately the same as in previ-
ous years. 
dengue feveR 
Dengue fever cases have been on the increase in re-
cent years, with 35 to 50 cases per year. In 2011, lab-
oratories reported 45 findings. 
otHeR tRavel-Related 
infectionS 
A significant percentage of the following infections 
are travel-related: legionella, salmonella, campylo-
bacter, shigella, EHEC, hepatitis A, hepatitis B, gon-
orrhoea, syphilis, HIV and AIDS, carbapenem-resist-
ant gram-negative bacilli and MMR diseases; the data 
on country of acquisition and means of transmission 
are discussed separately for each of the following in 
their respective sections.
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blood and cSf findingS in 
childRen
blood culture findings in children 
The number of blood culture positive cases in chil-
dren under 15 reported in 2011 was 551, roughly 
the same as in recent years (average between 2000 
and 2010 was 625, variation 530–687). Over half of 
the findings (296 out of 551) were in babies under 
12 months old. Among infants, Staphylococcus epi-
dermidis and other coagulase-negative staphylococci 
caused over 37% of blood culture positive infections. 
Though these bacteria belong to normal skin flora, 
they typically cause late-onset sepsis in newborn ba-
bies in intensive care. 
The second most common cause (14% of the find-
ings) was Streptococcus agalactiae (Group B strep-
tococcus, GBS). It is typically contracted from the 
mother’s birth canal during labour and causes an in-
fection (early-onset sepsis) in the newborn baby dur-
ing its first days of life. Other common causes of in-
fection were Escherichia coli (16% of the findings), 
Staphylococcus aureus (7%), Enterococcus faecalis (4%) 
and Streptococcus pneumoniae (4%), as expected. 
Coagulase-negative staphylococci and S. pneumoniae 
were the most common findings in children aged 1 to 
14 (16% and 29%, respectively), accounting for half 
of the reported cases in this age group. These were fol-
lowed by S. aureus (16%) and the Streptococcus viri-
dans group (8%). 
csf findings in children 
The number of bacterial and fungal findings related 
to children’s central nervous system infections re-
mained at the same level as in the preceding years, 
as did the distribution of pathogens. The number of 
cases reported in 2011 was 25 (annual average from 
2000 to 2010 was 38, variation 18−56), of which 
8 were diagnosed in infants under 12 months old. 
The most common findings in the age group of un-
der 12 months were S. agalactiae, pneumococci and 
S. epidermidis (Table 14); in the age group 1 to 14, 
the most common findings were meningococci, 
pneumococci and S. aureus. 
Gbs in newborns 
Between 1995 and 2011, an average of 33 cases per 
year of early-onset GBS in newborns (diagnosed from 
blood and/or CSF under the age of 7 days) were re-
ported; the variation was 22 to 57 cases per year, and 
the incidence was 0.4 to 1.0 per 1,000 live births. 
There were 22 cases in 2011 (0.4 cases per 1,000 live 
births). The average figure for late-onset GBS be-
tween 1995 and 2011 was 15 cases per year; the vari-
ation was 6 to 24 cases per year, and the incidence 
was 0.1 to 0.4 per 1,000 live births. There were 20 
cases in 2011 (0.3 cases per 1,000 live births).
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Staphylococcus epidermidis 50 76 76 61 110 98 100 92 87 64 71 76
Escherichia coli 43 39 40 39 37 41 44 42 38 38 45 48
Streptococcus agalactiae 38 41 46 37 45 73 55 51 49 51 54 42
Staphylococcus, other 
coagulase-negative
26 23 35 20 36 31 41 39 33 43 32 33
Staphylococcus aureus 18 17 24 21 32 32 37 25 23 22 24 21
Enterococcus faecalis 4 6 11 11 9 15 22 8 5 10 20 12
Streptococcus pneumoniae 26 19 17 25 28 26 27 21 26 25 20 11
Streptococcus viridans 
group
6 10 8 13 15 12 10 9 8 9 18 11
Enterobacter species 6 6 6 6 5 3 13 8 6 3 3 10
Klebsiella species 9 8 7 8 9 9 8 6 8 9 3 7
Serratia species 3 0 5 2 4 0 2 3 4 1 2 4
Acinetobacter species 1 0 4 3 1 1 3 2 1 1 3 2
Bacillus 1 2 0 1 2 2 1 4 4 2 1 1
Enterococcus faecium 4 1 2 2 3 2 3 0 1 2 2 1
Haemophilus, other than 
influenzae
0 0 0 1 0 1 1 0 1 0 0 1
Neisseria meningitidis 8 3 2 2 5 3 2 3 3 5 4 1
Propionibacterium species 1 0 1 0 0 0 0 1 0 0 0 1
Pseudomonas aeruginosa 0 2 1 1 4 0 0 0 2 0 2 1
Salmonella, other than Typhi 0 0 1 0 0 0 0 0 0 1 0 1
Bacteroides fragilis group 1 1 0 0 0 0 0 1 1 0 1 0
Citrobacter species 4 2 1 1 0 1 1 0 0 1 1 0
Clostridium perfringens 0 0 1 0 0 1 0 0 0 0 0 0
Clostridium, other or 
unidentified
1 1 0 1 1 0 2 0 1 1 1 0
Enterococcus, other or 
unidentified
0 0 0 0 1 0 0 0 0 2 0 0
Haemophilus influenzae 2 3 0 2 1 2 1 1 2 2 1 0
Listeria monocytogenes 1 1 0 0 0 0 2 1 0 1 2 0
Table 12. Blood culture findings in infants (under 12 months), 2000–2011 (no. of cases).
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Morganella morganii 1 0 0 0 0 0 0 0 0 0 0 0
Peptostreptococcus and  
Peptococcus
2 1 0 0 0 0 0 0 0 0 1 0
Prevotella species 0 0 0 0 0 0 0 0 1 0 0 0
Proteus mirabilis 0 0 0 0 1 0 1 1 0 0 0 0
Proteus vulgaris 1 0 0 0 0 0 0 0 0 0 0 0
Stenotrophomonas 
maltophilia
0 0 1 1 0 1 0 2 0 2 2 0
Streptococcus bovis group 1 0 1 1 1 1 0 0 0 2 0 0
Streptococcus milleri group 1 0 1 0 0 0 1 0 0 0 0 0
Streptococcus pyogenes 1 2 1 1 3 0 0 3 2 4 2 0
Streptococcus, other beta-
haemolytic
1 0 1 1 2 0 1 0 0 3 2 0
Veillonella species 0 0 0 0 0 0 1 0 0 0 0 0
Other bacteria 4 4 12 9 8 4 5 10 7 5 4 10
bacteria, total 265 268 305 270 363 359 384 333 313 309 321 294
Candida albicans 3 3 10 2 3 4 4 2 3 1 2 1
Other candida species 9 8 8 2 0 1 0 1 1 0 0 1
Other fungi 0 0 0 0 0 0 0 1 0 0 0 0
fungi, total 12 11 18 4 3 5 4 4 4 1 2 2
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Streptococcus pneumoniae 72 76 92 94 88 101 99 115 87 92 95 74
Staphylococcus aureus 44 38 58 47 58 41 37 43 40 36 43 42
Staphylococcus epidermidis 48 26 40 30 25 41 40 33 22 31 37 29
Streptococcus viridans 
group
18 23 13 13 18 24 24 23 21 25 36 20
Streptococcus pyogenes 9 9 10 12 4 0 9 13 11 11 6 16
Staphylococcus, other 
coagulase-negative
15 18 14 16 9 13 8 18 13 16 21 13
Escherichia coli 20 5 13 13 15 10 16 12 14 12 15 11
Haemophilus influenzae 2 2 1 5 0 2 1 2 3 3 2 5
Pseudomonas aeruginosa 6 7 4 6 3 6 3 2 1 3 7 4
Enterobacter species 2 0 1 6 3 3 1 2 4 3 2 3
Enterococcus faecalis 0 2 4 2 2 4 2 6 6 4 6 3
Bacillus 9 2 5 6 2 7 6 0 6 3 3 2
Bacteroides fragilis group 3 1 1 0 2 3 0 0 0 1 0 2
Klebsiella species 2 2 6 4 5 10 3 6 5 2 4 2
Neisseria meningitidis 9 9 8 6 2 7 5 3 4 0 6 2
Peptostreptococcus and 
Peptococcus
1 1 0 0 0 0 0 0 0 0 0 2
Salmonella Typhi 0 0 1 1 1 2 0 2 0 0 0 2
Salmonella, other than Typhi 1 1 1 1 1 1 2 5 2 0 6 2
Clostridium, other or 
unidentified
3 1 2 1 0 3 2 4 1 1 2 1
Fusobacterium species 4 1 3 0 1 2 3 5 5 1 1 1
Mycobacterium, other or 
unidentified
0 0 0 0 0 0 0 0 0 0 0 1
Streptococcus milleri group 2 1 1 0 0 3 2 0 2 2 2 1
Streptococcus, other beta-
haemolytic
1 1 0 3 2 2 4 1 0 2 2 1
Acinetobacter species 5 5 8 2 1 4 1 2 2 4 1 0
Bacteroides, other than 
fragilis group
1 0 0 0 0 0 0 0 0 0 0 0
Campylobacter species 2 1 0 0 0 0 0 0 0 0 0 0
Table 13. Blood culture findings in children (aged 1 to 14), 2000–2011 (no. of cases).
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Citrobacter species 1 1 1 0 0 1 0 2 2 1 1 0
Clostridium perfringens 0 0 0 1 0 0 1 2 0 1 1 0
Enterococcus faecium 2 2 4 1 2 2 3 4 2 7 7 0
Enterococcus, other or 
unidentified
0 0 0 2 2 0 2 2 3 0 1 0
Listeria monocytogenes 0 1 0 1 0 0 0 0 0 0 0 0
Prevotella species 0 0 0 0 1 0 0 0 0 0 0 0
Propionibacterium species 0 0 0 1 0 0 0 0 0 0 0 0
Proteus mirabilis 0 0 0 0 1 0 0 1 0 0 0 0
Pseudomonas, other than 
aeruginosa
1 3 1 1 0 1 0 1 0 3 0 0
Serratia species 0 0 1 0 0 1 2 1 0 0 1 0
Stenotrophomonas 
maltophilia
2 2 0 1 3 0 1 3 4 2 2 0
Streptococcus agalactiae 1 0 0 2 1 0 0 2 1 0 0 0
Streptococcus bovis group 0 0 0 0 0 0 1 0 0 0 0 0
Veillonella species 0 0 0 0 0 0 1 0 0 0 1 0
Yersinia pseudotuberculosis 0 0 0 1 0 0 0 0 0 0 0 0
Other bacteria 9 8 16 11 18 22 14 15 10 10 24 10
bacteria, total 295 249 309 290 270 316 293 330 271 276 335 249
Other candida species 1 0 0 0 1 0 2 3 1 0 0 2
Candida albicans 4 1 2 1 0 1 1 0 2 0 2 0
Other fungi 0 0 1 2 0 0 2 1 0 0 0 1
fungi, total 5 1 3 3 1 1 5 4 3 0 2 3
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Staphylococcus epidermidis 0 1 3 3 3 3 3 2 1 2 2 2
Streptococcus agalactiae 4 2 5 1 10 7 7 6 3 6 8 2
Streptococcus pneumoniae 0 0 3 6 8 3 1 4 3 2 3 2
Escherichia coli 0 3 1 1 2 0 2 1 1 1 2 1
Streptococcus viridans 
group
0 0 0 1 0 0 0 0 0 2 0 1
Acinetobacter species 0 0 1 0 0 0 1 0 0 0 0 0
Bacillus 0 0 0 0 0 0 1 0 0 0 0 0
Bacteroides, other than 
fragilis group
0 0 0 0 0 0 0 1 0 0 0 0
Citrobacter species 0 0 0 0 0 0 0 1 0 0 1 0
Enterobacter species 0 0 0 0 1 0 0 0 0 0 0 0
Enterococcus faecalis 0 0 0 1 1 0 2 1 0 0 0 0
Enterococcus faecium 0 0 0 0 0 0 1 0 0 0 0 0
Haemophilus influenzae 1 1 0 1 0 1 0 0 0 1 0 0
Klebsiella species 0 0 0 0 0 0 0 0 0 1 0 0
Mycobacterium, other than 
avium
0 0 0 0 0 0 0 0 0 0 1 0
Neisseria meningitidis 5 4 1 2 4 0 1 2 1 2 1 0
Propionibacterium species 0 0 0 1 1 0 0 0 0 0 0 0
Serratia species 0 0 0 0 1 0 0 0 0 0 0 0
Staphylococcus aureus 1 0 0 3 2 1 0 1 2 2 1 0
Staphylococcus, other 
coagulase-negative
0 0 4 1 2 1 0 0 4 1 0 0
Streptococcus pyogenes 0 0 0 0 0 0 0 0 0 1 0 0
Other bacteria 0 0 2 1 1 0 0 0 0 1 0 0
bacteria, total 11 11 20 22 36 16 19 19 15 22 19 8
Candida albicans 0 0 0 0 0 0 0 0 0 1 0 0
fungi, total 0 0 0 0 0 0 0 0 0 1 0 0
Table 14. Cerebrospinal fluid culture findings in infants (under 12 months), 2000–2011 (no. of cases).
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Table 15. Cerebrospinal fluid culture findings in children (aged 1 to 14), 2000–2011 (no. of cases).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Neisseria meningitidis 6 5 7 4 4 5 7 5 3 2 3 4
Streptococcus pneumoniae 0 0 2 10 2 1 5 5 2 4 2 3
Staphylococcus aureus 1 0 1 2 2 0 0 2 3 3 2 2
Staphylococcus epidermidis 0 0 7 1 4 2 0 1 5 2 1 2
Haemophilus influenzae 1 1 0 2 0 0 0 0 0 0 0 1
Propionibacterium species 0 0 0 0 0 1 0 0 0 0 0 1
Acinetobacter species 0 0 1 0 1 1 0 0 0 0 0 0
Bacteroides fragilis group 0 0 0 0 0 0 1 0 0 0 0 0
Citrobacter species 0 0 1 0 0 0 0 0 0 0 0 0
Corynebacterium species 0 0 0 0 0 0 0 0 2 0 1 0
Enterobacter species 0 0 0 0 1 0 0 0 0 1 0 0
Enterococcus faecalis 1 0 0 0 1 1 0 0 0 0 1 0
Enterococcus faecium 0 0 1 0 1 0 0 0 0 0 0 0
Escherichia coli 1 0 0 0 0 0 1 0 0 0 0 0
Mycobacterium, other than 
avium
0 0 0 1 0 0 0 0 0 0 0 0
Peptostreptococcus and 
Peptococcus
0 0 0 0 0 0 1 0 0 0 0 0
Staphylococcus, other 
coagulase-negative
0 0 3 2 2 2 0 0 0 1 0 0
Stenotrophomonas 
maltophilia
0 0 0 1 0 0 0 0 0 0 0 0
Streptococcus agalactiae 0 1 0 0 0 0 0 0 0 0 0 0
Streptococcus pyogenes 0 0 1 0 0 0 0 0 0 0 0 0
Streptococcus viridans 
group
0 0 0 1 1 0 2 0 0 0 0 0
Streptococcus, other beta-
haemolytic
0 0 1 0 0 0 0 0 0 1 0 0
Other bacteria 0 0 5 0 0 5 1 0 6 3 1 4
bacteria, total 10 7 30 24 19 18 18 13 21 17 11 17
Candida albicans 0 0 0 0 1 0 0 0 0 0 0 0
fungi, total 0 0 0 0 1 0 0 0 0 0 0 0
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blood and cSf findingS in 
adultS
blood culture findings in adults 
The total number of blood culture findings in adults 
has grown steadily and exceeded 11,000 in 2011 (2010: 
10,874). Gram-positive bacteria were more common 
in the working-age population (aged 15 to 64) and 
gram-negative bacteria among those aged 65 or more. 
Anaerobic bacteria constituted 4% and fungi 2% of all 
blood culture positive findings among adults. 
In the working-age population, the most common bac-
terial finding in 2011 was Escherichia coli, constituting 
more than 20% of all cases (Table 16). The next most 
common findings were Staphylococcus aureus (15%), 
Streptococcus pneumoniae (9%) coagulase-negative sta-
phylococci (9%), and Klebsiella species (4%). 
E. coli was also the most common blood culture find-
ing among patients aged 65 years or more, accounting 
for a third of all findings (Table 17). The next most 
common findings were Staphylococcus aureus (11%), 
coagulase-negative staphylococci (7%), Klebsiella spe-
cies (7%) and Streptococcus pneumoniae (4%). 
csf findings in adults 
There were 131 reported cases of microbial findings 
in CSF in adults in 2011; the annual average for the 
period 2000 to 2010 was 144, variation 32–193. Pa-
tients over the age of 65 accounted for 27% of the 
cases (35 out of 131). 
Coagulase-negative staphylococci were reported in 
17% of the cases in working-age patients (Table 19). 
The most common actual pathogens were pneumo-
coccus (13%), S. aureus (21%) and meningococcus 
(7%). 
In patients aged 65 years or older, coagulase-negative 
staphylococci accounted for 14% of the findings (Ta-
ble 20). The most commonly reported actual path-
ogens were pneumococcus (20%), S. aureus (14%), 
and Listeria monocytogenes (11%). 
Group a streptococcus 
The prevalent emm types of group A streptococ-
cus (Streptococcus pyogenes) were emm1, emm28 and 
emm89, as in previous years. The percentage of the 
previously common emm type emm84 began to de-
cline in 2008 and is now low (2%) (Table 18). Re-
cently emerging emm types include emm12 and 
emm119, of which emm12 accounted for 10% of the 
cases and emm119 for 4% (Table 18).
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Table 16. Blood culture findings in patients aged 15 to 64, 2000–2011 (no. of cases).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Escherichia coli 533 613 580 645 707 780 797 837 871 885 930 933
Staphylococcus aureus 409 451 462 448 488 459 565 549 529 540 585 645
Streptococcus pneumoniae 312 343 333 406 386 377 348 353 480 441 415 393
Staphylococcus epidermidis 278 300 305 286 294 286 281 265 279 313 264 223
Klebsiella species 115 114 134 121 159 184 145 159 198 187 207 163
Staphylococcus, other 
coagulase-negative 123 106 138 114 126 113 120 141 151 137 139 143
Streptococcus viridans 
group 119 118 105 126 141 141 130 118 140 144 150 139
Streptococcus, other beta-
haemolytic 59 66 78 79 101 96 127 117 113 113 131 138
Bacteroides fragilis group 69 64 61 59 67 83 85 82 109 68 110 109
Enterococcus faecium 39 61 53 51 45 66 69 81 91 89 91 108
Streptococcus pyogenes 84 60 93 78 100 76 105 133 157 117 113 102
Enterococcus faecalis 67 95 99 84 80 100 83 105 83 107 86 97
Pseudomonas aeruginosa 79 72 73 85 58 88 62 72 74 78 91 92
Enterobacter species 75 92 53 60 62 49 77 70 69 82 99 86
Streptococcus milleri group 48 46 48 48 48 54 62 64 72 57 68 86
Streptococcus agalactiae 63 76 78 68 64 99 76 83 96 95 110 75
Bacillus 23 20 18 22 15 18 22 24 25 21 32 34
Salmonella, other than 
Typhi 21 37 12 22 35 29 51 59 48 26 42 33
Serratia species 8 10 12 14 10 16 18 19 24 27 20 32
Fusobacterium species 17 26 15 21 32 31 19 31 31 27 37 31
Peptostreptococcus and 
Peptococcus 15 20 22 23 15 21 18 11 12 27 15 30
Citrobacter species 19 18 14 10 21 15 28 19 23 29 31 28
Haemophilus influenzae 14 14 9 14 12 13 9 26 18 19 18 22
Acinetobacter species 18 9 13 10 16 16 10 21 13 18 14 21
Clostridium, other or 
unidentified 35 26 28 14 17 22 20 15 19 20 22 19
Capnocytophaga 
canimorsus 3 6 6 6 6 8 8 8 8 11 11 17
Neisseria meningitidis 13 19 20 18 18 16 20 21 9 13 14 17
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Proteus mirabilis 18 20 15 11 15 12 18 14 14 18 26 17
Prevotella species 6 11 4 11 11 15 11 8 13 13 15 16
Veillonella species 4 4 2 3 1 6 3 5 3 7 5 13
Enterococcus, other or 
unidentified 5 9 14 10 10 11 6 4 7 13 13 12
Propionibacterium species 20 19 8 11 6 9 7 5 3 9 6 9
Stenotrophomonas 
maltophilia 11 15 14 6 12 12 7 5 15 12 12 9
Clostridium perfringens 6 8 6 9 6 16 11 12 10 16 16 8
Morganella morganii 7 4 3 4 4 3 8 7 14 8 6 8
Bacteroides, other than 
fragilis group 2 6 5 0 5 2 4 3 5 10 1 7
Listeria monocytogenes 9 7 9 12 7 10 10 9 8 9 15 7
Pseudomonas, other than 
aeruginosa 2 2 3 4 5 4 0 4 9 7 7 7
Streptococcus bovis group 4 3 2 2 3 8 5 7 1 6 7 6
Campylobacter species 10 14 7 10 13 5 3 8 7 11 10 4
Haemophilus, other than 
influenzae 1 8 4 1 5 6 3 3 3 0 2 3
Salmonella Typhi 0 1 1 3 4 3 3 4 1 3 9 3
Hafnia alvei 4 1 1 5 4 3 0 1 3 6 2 2
Mycobacterium avium 2 3 0 1 0 2 2 2 1 2 2 2
Mycobacterium, other or 
unidentified 1 1 1 4 0 1 2 3 1 0 0 2
Proteus vulgaris 1 3 0 3 4 3 7 3 2 3 2 2
Yersinia enterocolitica 0 1 0 0 0 1 0 0 0 1 1 0
Yersinia pseudotuberculosis 1 2 2 1 1 0 0 0 1 0 0 0
Other bacteria 63 58 92 84 89 93 97 84 103 99 90 93
bacteria, total 2835 3082 3055 3127 3328 3481 3562 3674 3966 3944 4092 4046
Candida albicans 41 44 29 43 45 42 54 55 55 55 57 74
Other candida species 15 27 23 35 24 22 22 25 42 28 37 30
Other fungi 0 0 2 1 2 1 2 2 4 5 2 5
fungi, total 56 71 54 79 71 65 78 82 101 88 96 109
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Table 17. Blood culture findings in patients aged 65 or over, 2000–2011 (no. of cases).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Escherichia coli 1033 1179 1213 1314 1466 1624 1706 1760 1890 2056 2233 2481
Staphylococcus aureus 415 406 452 467 486 484 602 570 676 692 731 783
Klebsiella species 201 241 230 253 341 339 326 338 420 462 468 473
Staphylococcus  
epidermidis 228 253 228 231 254 284 265 275 299 270 325 315
Streptococcus 
pneumoniae 189 216 200 241 239 229 270 294 326 294 303 296
Enterococcus faecalis 144 142 149 146 192 183 202 220 217 222 229 274
Streptococcus, other beta-
haemolytic 88 105 100 123 135 140 174 171 177 222 258 266
Bacteroides fragilis group 96 104 96 118 120 135 119 135 146 164 178 203
Enterococcus faecium 61 61 48 76 97 74 108 132 126 175 180 198
Pseudomonas aeruginosa 119 132 148 148 139 151 154 188 191 184 218 196
Enterobacter species 79 97 87 97 92 115 95 105 131 128 156 157
Staphylococcus, other 
coagulase-negative 120 108 134 112 114 116 129 139 165 155 143 156
Streptococcus viridans 
group 74 93 83 103 103 106 110 115 140 135 132 138
Streptococcus agalactiae 53 61 49 62 76 84 81 77 94 104 126 113
Proteus mirabilis 61 51 57 62 80 57 68 93 99 102 106 97
Citrobacter species 26 39 40 44 43 42 42 35 65 59 76 59
Streptococcus milleri 
group 42 30 28 43 45 50 67 54 53 62 59 58
Serratia species 15 30 15 28 18 33 27 33 50 37 59 56
Clostridium perfringens 23 31 26 27 32 29 36 39 34 49 40 51
Streptococcus pyogenes 21 28 46 28 33 34 48 58 50 61 50 51
Haemophilus influenzae 17 27 15 13 13 28 21 25 21 22 19 37
Enterococcus, other or 
unidentified 7 21 18 19 16 17 19 15 24 20 24 33
Listeria monocytogenes 7 15 11 19 18 20 26 26 26 20 44 31
Morganella morganii 12 9 13 10 14 21 14 26 11 18 29 30
Peptostreptococcus and 
Peptococcus 15 9 14 20 13 17 22 25 14 29 36 26
Clostridium, other or 
unidentified 28 25 23 18 25 21 22 31 18 27 35 24
Acinetobacter species 13 18 17 8 13 10 18 11 12 16 16 17
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Bacillus 13 17 11 10 10 10 17 9 11 12 7 14
Fusobacterium species 6 6 16 7 13 10 9 15 10 8 17 14
Prevotella species 5 8 11 4 11 10 10 8 11 15 13 14
Propionibacterium species 19 12 15 4 8 13 9 4 5 9 10 13
Streptococcus bovis group 9 10 7 9 20 12 17 17 15 25 12 12
Bacteroides, other than 
fragilis group 7 5 3 5 8 4 3 5 8 13 8 8
Proteus vulgaris 4 8 7 8 7 9 9 9 4 4 8 8
Pseudomonas, other than 
aeruginosa 9 3 6 6 3 7 9 11 10 11 10 8
Salmonella, other than 
Typhi 5 4 7 5 6 15 11 8 19 6 8 7
Capnocytophaga 
canimorsus 3 1 1 1 1 1 4 2 3 2 2 6
Neisseria meningitidis 5 4 4 4 3 2 5 2 6 6 6 6
Veillonella species 3 0 0 1 1 7 2 6 9 5 4 6
Stenotrophomonas 
maltophilia 4 8 3 6 10 6 10 8 3 6 7 4
Campylobacter species 2 3 3 1 5 3 5 3 5 6 3 1
Hafnia alvei 3 7 1 1 4 4 3 6 8 7 7 1
Mycobacterium, other or 
unidentified 2 2 0 2 3 0 5 1 2 0 5 1
Haemophilus, other than 
influenzae 0 0 2 1 3 2 2 1 1 1 1 0
Mycobacterium avium 0 0 1 0 0 1 0 0 1 0 0 0
Salmonella Typhi 0 0 0 1 0 1 0 0 0 0 0 0
Yersinia enterocolitica 3 1 1 3 1 1 1 1 0 1 1 0
Yersinia 
pseudotuberculosis 0 2 1 1 2 2 1 1 0 3 1 0
Other bacteria 66 59 68 87 96 96 96 82 124 123 121 143
bacteria, total 3355 3691 3708 3997 4432 4659 4999 5189 5730 6048 6524 6885
Candida albicans 41 48 39 63 51 39 54 56 66 49 93 65
Other candida species 27 22 31 46 27 25 22 27 25 42 33 44
Other fungi 0 1 0 3 0 3 0 0 2 0 0 4
fungi, total 68 71 70 112 78 67 76 83 93 91 126 113
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cases 
notified to 
nidR
stains  
examined
emm1 emm28 emm84 emm89 other nt
2006 163 25 (15 %) 33 (20 %) 24 (15 %) 11 (7 %) 59 (36 %) 11 (7 %)
2007 205 58 (28 %) 26 (13 %) 32 (16 %) 12 (6 %) 72 (35 %) 5 (2 %)
2008 225 52 (23 %) 47 (21 %) 9 (4 %)  10 (4 %) 102 (45 %) 5 (2 %)
2009 191 25 (13 %) 56 (29 %) 4 (2 %) 29 (15 %) 74 (39 %) 3 (2 %)
2010 167 22 (13 %) 37 (22 %) 4 (2 %) 26 (16 %) 77 (46 %) 1 (<1 %)
2011 163 25 (15%) 37 (23%) 4 (2%) 30 (18%) 66 (40%) 1 (<1 %)
Table 18. Group A Streptococcus blood findings by emm-type, 2006–2011 (no. of cases and %).
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Table 19. Cerebrospinal fluid culture findings in patients aged 15 to 64, 2000–2011 (no. of cases).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Staphylococcus aureus 11 0 6 10 17 10 9 16 13 13 12 20
Streptococcus 
pneumoniae 1 4 19 26 21 16 17 14 26 19 15 12
Staphylococcus 
epidermidis 1 1 27 21 24 34 32 17 27 18 11 10
Neisseria meningitidis 13 12 19 15 11 15 20 16 4 9 6 7
Staphylococcus, other 
coagulase-negative 0 0 12 6 16 14 12 7 14 10 8 6
Propionibacterium species 0 0 6 6 11 5 5 5 4 4 7 4
Streptococcus viridans 
group 0 0 6 2 1 4 7 2 1 2 2 4
Enterococcus faecalis 3 3 2 3 5 3 4 5 4 3 4 3
Acinetobacter species 0 0 2 1 1 3 3 5 2 3 0 2
Enterobacter species 0 0 1 0 3 5 2 2 9 3 1 2
Enterococcus faecium 0 0 1 0 2 1 0 1 0 1 0 2
Haemophilus influenzae 1 4 2 0 1 0 0 0 3 1 0 2
Haemophilus, other than 
influenzae 0 0 0 0 0 0 0 1 0 0 0 2
Klebsiella species 0 0 0 0 0 0 0 0 4 2 1 2
Streptococcus, other beta-
haemolytic 0 0 2 0 1 1 0 0 1 2 1 2
Enterococcus, other or 
unidentified 0 1 1 0 0 0 1 1 1 0 0 1
Escherichia coli 2 0 3 0 0 7 4 3 3 4 1 1
Listeria monocytogenes 0 1 0 2 1 0 2 1 1 2 1 1
Proteus mirabilis 0 0 0 0 0 0 0 0 0 0 0 1
Pseudomonas aeruginosa 0 0 5 4 2 4 6 3 4 5 3 1
Pseudomonas, other than 
aeruginosa 0 0 0 1 0 0 1 1 1 1 0 1
Salmonella, other than 
Typhi 0 1 0 1 0 0 0 0 2 0 0 1
Serratia species 0 0 0 2 1 1 0 3 0 0 0 1
Stenotrophomonas 
maltophilia 0 0 0 0 1 0 0 1 0 0 0 1
Streptococcus pyogenes 0 0 1 1 0 0 1 0 2 2 1 1
Bacillus 0 0 5 0 0 3 6 4 3 0 0 0
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Campylobacter species 0 0 0 0 0 1 0 0 0 0 0 0
Capnocytophaga 
canimorsus 0 0 0 0 0 0 0 0 0 1 0 0
Citrobacter species 0 0 0 1 1 2 0 1 0 0 1 0
Corynebacterium species 0 0 0 1 1 2 1 1 0 1 0 0
Morganella morganii 0 0 1 0 0 0 0 0 0 0 0 0
Mycobacterium, other 
than avium 2 0 2 1 0 0 0 1 2 0 0 0
Peptostreptococcus and 
Peptococcus 0 0 0 2 0 0 0 0 0 1 0 0
Prevotella species 0 0 1 0 0 0 0 0 0 0 0 0
Streptococcus agalactiae 0 0 1 0 2 0 1 5 2 0 2 0
Streptococcus bovis group 0 0 0 0 0 0 0 0 0 0 1 0
Streptococcus milleri 
group 0 0 0 0 0 0 0 0 1 0 0 0
Other bacteria 0 0 6 3 3 5 10 7 5 7 2 6
bacteria, total 34 27 131 109 126 136 144 123 139 114 80 96
Candida albicans 0 0 1 1 2 1 0 1 0 0 0 0
Other candida species 0 0 1 0 3 1 3 4 1 0 1 0
Other fungi 0 0 0 0 0 0 0 1 0 0 0 0
fungi, total 0 0 2 1 5 2 3 6 1 0 1 0
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Table 20. Cerebrospinal fluid culture findings in patients aged 65 or over, 2000–2011 (no. of cases).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Streptococcus pneumoniae 0 0 4 5 4 8 10 4 7 10 6 7
Staphylococcus aureus 2 0 2 7 7 5 3 2 3 6 5 5
Listeria monocytogenes 0 1 2 4 2 4 3 2 2 2 6 4
Staphylococcus 
epidermidis 0 1 7 5 6 10 9 12 10 6 2 4
Bacillus 0 0 3 0 0 0 0 0 1 0 0 2
Escherichia coli 1 1 1 2 2 1 1 0 1 1 1 2
Citrobacter species 0 0 0 0 0 0 0 0 0 0 0 1
Enterobacter species 0 0 2 0 1 0 0 1 0 0 1 1
Haemophilus influenzae 0 0 0 0 0 1 2 2 1 1 0 1
Mycobacterium, other 
than avium 2 1 1 4 1 3 0 0 1 1 0 1
Propionibacterium species 0 1 4 0 1 0 2 0 2 2 1 1
Staphylococcus, other 
coagulase-negative 0 0 5 4 5 5 3 2 3 3 3 1
Acinetobacter species 0 0 2 1 0 0 1 1 0 0 0 0
Bacteroides fragilis group 0 0 0 0 0 0 0 0 0 1 0 0
Corynebacterium species 0 0 0 1 0 0 0 0 0 0 1 0
Enterococcus faecalis 1 1 2 3 0 2 2 3 0 1 0 0
Enterococcus faecium 0 0 0 1 0 0 0 0 0 1 0 0
Enterococcus, other or 
unidentified 0 0 1 0 0 0 0 0 0 0 1 0
Klebsiella species 0 0 0 0 0 0 0 0 1 1 0 0
Mycobacterium avium 0 0 0 0 0 1 0 0 0 0 0 0
Neisseria meningitidis 0 1 0 1 1 2 1 0 1 0 2 0
Peptostreptococcus and 
Peptococcus 0 0 0 1 0 0 0 0 0 0 0 0
Proteus mirabilis 0 0 0 0 0 0 0 0 1 1 0 0
Proteus vulgaris 0 0 0 0 0 1 0 0 0 0 0 0
Pseudomonas aeruginosa 0 0 0 0 1 0 1 0 2 0 0 0
Pseudomonas, other than 
aeruginosa 0 0 0 0 1 0 0 0 0 0 0 0
Serratia species 0 0 0 0 1 0 0 0 0 0 0 0
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Stenotrophomonas 
maltophilia 0 0 0 0 1 0 0 0 0 0 0 0
Streptococcus agalactiae 4 2 0 1 0 0 0 0 0 1 1 0
Streptococcus bovis group 0 0 0 0 0 0 0 0 0 1 0 0
Streptococcus milleri 
group 0 0 0 0 0 0 0 0 0 1 0 0
Streptococcus pyogenes 0 0 2 0 0 0 0 0 0 0 0 0
Streptococcus viridans 
group 0 0 1 0 1 0 1 1 0 3 1 0
Streptococcus, other beta-
haemolytic 0 0 0 2 0 1 0 0 0 1 0 0
Other bacteria 0 0 3 2 1 2 3 2 1 1 5 3
bacteria, total 10 9 42 44 36 46 42 32 37 45 36 33
Other candida species 0 0 2 0 1 0 2 0 0 2 0 2
Candida albicans 0 0 0 0 0 1 0 0 1 0 0 0
fungi, total 0 0 2 0 1 1 2 0 1 2 0 2
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Table 21. Blood culture findings in all age groups, 2000–2011 (no. of cases).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Escherichia coli 1629 1836 1846 2011 2225 2455 2563 2651 2813 2991 3223 3473
Staphylococcus aureus 886 912 996 983 1064 1016 1241 1187 1268 1290 1383 1491
Streptococcus pneumoniae 599 654 642 766 741 733 744 783 919 852 833 774
Klebsiella species 327 365 377 386 514 542 482 509 631 660 682 645
Staphylococcus epidermidis 604 655 649 608 683 709 686 665 687 678 697 643
Streptococcus, other beta-
haemolytic 149 172 179 206 240 238 306 289 290 340 393 405
Enterococcus faecalis 215 245 263 243 283 302 309 339 311 343 341 386
Staphylococcus, other 
coagulase-negative 284 255 321 262 285 273 298 337 362 351 335 345
Bacteroides fragilis group 169 170 158 177 189 221 204 218 256 233 289 314
Streptococcus viridans 
group 217 244 209 255 277 283 274 265 309 313 336 308
Enterococcus faecium 106 125 107 130 147 144 183 217 220 273 280 307
Pseudomonas aeruginosa 204 213 226 240 204 245 219 262 268 265 318 293
Enterobacter species 162 195 147 169 162 170 186 185 210 216 260 256
Streptococcus agalactiae 155 178 173 169 186 256 212 213 240 250 290 230
Streptococcus pyogenes 115 99 150 119 140 110 162 207 220 193 171 169
Streptococcus milleri group 93 77 78 91 93 107 132 118 127 121 129 145
Proteus mirabilis 79 71 72 73 97 69 87 109 113 120 132 114
Serratia species 26 40 33 44 32 50 49 56 78 65 82 92
Citrobacter species 50 60 56 55 64 59 71 56 90 90 109 87
Haemophilus influenzae 35 46 25 34 26 45 32 54 44 46 40 64
Clostridium perfringens 29 39 33 37 38 46 48 53 44 66 57 59
Peptostreptococcus and 
Peptococcus 33 31 36 43 28 38 40 36 26 56 52 58
Bacillus 46 41 34 39 29 37 46 37 46 38 43 51
Fusobacterium species 27 33 34 28 46 43 31 51 46 36 55 46
Enterococcus, other or 
unidentified 12 30 32 31 29 28 27 21 34 35 38 45
Clostridium, other or 
unidentified 67 53 53 34 43 46 46 50 39 49 60 44
Salmonella, other than 
Typhi 27 42 21 28 42 45 64 72 69 33 56 43
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Acinetobacter species 37 32 42 23 31 31 32 36 28 39 34 40
Listeria monocytogenes 17 24 20 32 25 30 38 36 34 30 61 38
Morganella morganii 20 13 16 14 18 24 22 33 25 26 35 38
Prevotella species 11 19 15 15 23 25 21 16 25 28 28 30
Neisseria meningitidis 35 35 34 30 28 28 32 29 22 24 30 26
Capnocytophaga 
canimorsus 6 7 7 7 7 9 12 10 11 13 13 23
Propionibacterium species 40 31 24 16 14 22 16 10 8 18 16 23
Veillonella species 7 4 2 4 2 13 7 11 12 12 10 19
Streptococcus bovis group 14 13 10 12 24 21 23 24 16 33 19 18
Bacteroides, other than 
fragilis group 10 11 8 5 13 6 7 8 13 23 9 15
Pseudomonas, other than 
aeruginosa 12 8 10 11 8 12 9 16 19 21 17 15
Stenotrophomonas 
maltophilia 17 25 18 14 25 19 18 18 22 22 23 13
Proteus vulgaris 6 11 7 11 11 12 16 12 6 7 10 10
Campylobacter species 14 18 10 11 18 8 8 11 12 17 13 5
Salmonella Typhi 0 1 2 5 5 6 3 6 1 3 9 5
Haemophilus, other than 
influenzae 1 8 6 3 8 9 6 4 5 1 3 4
Mycobacterium, other or 
unidentified 3 3 1 6 3 1 7 4 3 0 5 4
Hafnia alvei 7 8 2 6 8 7 3 7 11 13 9 3
Mycobacterium avium 2 3 1 1 0 3 2 2 2 2 2 2
Yersinia enterocolitica 3 2 1 3 1 2 1 1 0 2 2 0
Yersinia pseudotuberculosis 1 4 3 3 3 2 1 1 1 3 1 0
Other bacteria 142 129 188 191 211 215 212 191 244 237 239 256
bacteria, total 6750 7290 7377 7684 8393 8815 9238 9526 10280 10577 11272 11474
Candida albicans 89 96 80 109 99 86 113 113 126 105 154 140
Other candida species 52 57 62 83 52 48 46 56 69 70 70 77
Other fungi 0 1 3 6 2 4 4 4 6 5 2 10
fungi, total 141 154 145 198 153 138 163 173 201 180 226 227
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Table 22. Cerebrospinal fluid culture findings in all age groups, 2000–2011 (no. of cases).
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Staphylococcus aureus 15 0 9 22 28 16 12 21 21 24 20 27
Streptococcus pneumoniae 1 4 28 47 35 28 33 27 38 35 26 24
Staphylococcus 
epidermidis 1 3 44 30 37 49 44 32 43 28 16 18
Neisseria meningitidis 24 22 27 22 20 22 29 23 9 13 12 11
Staphylococcus, other 
coagulase-negative 0 0 24 13 25 22 15 9 21 15 11 7
Propionibacterium species 0 1 10 7 13 6 7 5 6 6 8 6
Listeria monocytogenes 0 2 2 6 3 4 5 3 3 4 7 5
Streptococcus viridans 
group 0 0 7 4 3 4 10 3 1 7 3 5
Escherichia coli 4 4 5 3 4 8 8 4 5 6 4 4
Haemophilus influenzae 3 6 2 3 1 2 2 2 4 3 0 4
Enterobacter species 0 0 3 0 6 5 2 3 9 4 2 3
Enterococcus faecalis 5 4 4 7 7 6 8 9 4 4 5 3
Acinetobacter species 0 0 6 2 2 4 5 6 2 3 0 2
Bacillus 0 0 8 0 0 3 7 4 4 0 0 2
Enterococcus faecium 0 0 2 1 3 1 1 1 0 2 0 2
Haemophilus, other than 
influenzae 0 0 0 0 0 0 0 1 0 0 0 2
Klebsiella species 0 0 0 0 0 0 0 0 5 4 1 2
Streptococcus agalactiae 8 5 6 2 12 7 8 11 5 7 11 2
Streptococcus, other beta-
haemolytic 0 0 3 2 1 2 0 0 1 4 1 2
Citrobacter species 0 0 1 1 1 2 0 2 0 0 2 1
Enterococcus, other or 
unidentified 0 1 2 0 0 0 1 1 1 0 1 1
Mycobacterium, other 
than avium 4 1 3 6 1 3 0 1 3 1 1 1
Proteus mirabilis 0 0 0 0 0 0 0 0 1 1 0 1
Pseudomonas aeruginosa 0 0 5 4 3 4 7 3 6 5 3 1
Pseudomonas, other than 
aeruginosa 0 0 0 1 1 0 1 1 1 1 0 1
Salmonella, other than 
Typhi 0 1 0 1 0 0 0 0 2 0 0 1
Serratia species 0 0 0 2 3 1 0 3 0 0 0 1
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Stenotrophomonas 
maltophilia 0 0 0 1 2 0 0 1 0 0 0 1
Streptococcus pyogenes 0 0 4 1 0 0 1 0 2 3 1 1
Bacteroides fragilis group 0 0 0 0 0 0 1 0 0 1 0 0
Bacteroides, other than 
fragilis group 0 0 0 0 0 0 0 1 0 0 0 0
Campylobacter species 0 0 0 0 0 1 0 0 0 0 0 0
Capnocytophaga 
canimorsus 0 0 0 0 0 0 0 0 0 1 0 0
Corynebacterium species 0 0 0 2 1 2 1 1 2 1 2 0
Morganella morganii 0 0 1 0 0 0 0 0 0 0 0 0
Mycobacterium avium 0 0 0 0 0 1 0 0 0 0 0 0
Peptostreptococcus and 
Peptococcus 0 0 0 3 0 0 1 0 0 1 0 0
Prevotella species 0 0 1 0 0 0 0 0 0 0 0 0
Proteus vulgaris 0 0 0 0 0 1 0 0 0 0 0 0
Streptococcus bovis group 0 0 0 0 0 0 0 0 0 1 1 0
Streptococcus milleri 
group 0 0 0 0 0 0 0 0 1 1 0 0
Other bacteria 0 0 16 6 5 12 14 9 12 12 8 13
bacteria, total 65 54 223 199 217 216 223 187 212 198 146 154
Other candida species 0 0 3 0 4 1 5 4 1 2 1 2
Candida albicans 0 0 1 1 3 2 0 1 1 1 0 0
Other fungi 0 0 0 0 0 0 0 1 0 0 0 0
fungi, total 0 0 4 1 7 3 5 6 2 3 1 2
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